AVI BIOPHARMA - Schweinegrippe-Profiteur

AVI Biopharma entwickelt das Grippemittel Neugene, welches laut Tests effektiv gegen verschiedene Grippestämme wirkt.

Wkn: 908085

Outstanding Shares: 85.644.698 Aktien (Stand: 6.3.2009)

 

Die Aktie wird in Deutschland  und an der NASDAQ gehandelt und erzielt bereits Umsätze in Millionenhöhe. Das Unternehmen verfügte zum 31.12.2008 über Assets von über 25 Millionen USD und hatte Schulden von insgesamt ca. 7 Millionen USD. Der Cashbestand beläuft sich auf ca. 11,5 Millionen USD.

http://secfilings.nasdaq.com/...DK&RcvdDate=3%2F10%2F2009&pdf=

Im Jahre 2006 ging es während SARS bis auf über 7 Euro hoch! 

Eine "Schweinegrippe-Aktie" die noch nicht gestiegen ist, wird es wohl kaum geben. Ein weiterer Favorit von mir, Biocryst, ging heute richtig ab und ich bin leider nicht mehr reingekommen.

Wer vom "Schweinegrippe-Hype" jetzt noch profitieren will, sollte einen Einstieg prüfen!

Den ersten Nachfrageschub erlebte der flüssige Virenkiller mit Ausbruch der Lungenseuche SARS in Asien. \"In der Folge haben wir erhöhte Bestellungen registriert, als das Virus auf Osteuropa und die Türkei übergriff\", so Schlegel. Mit dem Anflug der Vogelgrippe auf Westeuropa steigt aber auch hier der Bedarf an Desinfektionsmitteln kräftig an. Schlegel weiß: Wer mit Spritzmitteln gegen das Virus vorgehen will, kommt an Lanxess kaum vorbei: \"Wir sind einer der weltweit führenden Anbieter von industriellen Bioziden und Materialschutzstoffen.\" Innerhalb des Konzerns gehört Preventol zum Segment Performance Chemicals, das 2004 einen Umsatz von 1,91 Milliarden Euro erwirtschaftet hat. Preventol ist zwar kein Milliarden-Produkt, aber eine Innovation, die finanziell lukrativ ist. Schlegel kennt das Geschäft in- und auswendig. Seit 24 Jahren ist der studierte Kaufmann bei Bayer beziehungsweise dem vor einem Jahr abgespalteten Chemiekonzern Lanxess tätig – anfangs im Sektor Pflanzenschutz, danach für den Bereich Consumer-Produkte in den Vereinigten Staaten und in Argentinien. Seit fünf Jahren kümmert sich der begeisterte Basketballspieler und Jogger nunmehr in Leverkusen um Produkte für den Materialschutz. \"In diesem Job\", sagt der 45jährige, \"muß man komplexe naturwissenschaftliche Probleme analysieren, um innovative Produkte für Mensch und Tier zu entwickeln. Weil es dabei immer wieder neue Herausforderungen gibt, sollte man eine gewisse Leidenschaft mitbringen.\"

Dabei wird der Kampf gegen das Vogelgrippe-Virus nicht nur mit Desinfektionsmitteln geführt. Vor allem Biotech-Firmen arbeiten an Testsystemen und Impfstoffen. So wie Qiagen. Das Unternehmen hat zwei Tests zum Nachweis von Grippe und Vogelgrippe bei Tieren auf den Markt gebracht. Die sind hochempfindlich – und schnell: Die Ergebnisse liegen innerhalb von 75 Minuten vor. Allerdings will das Qiagen-Management nichts von einem Vogelgrippe-Hype wissen. \"Bislang sind die Umsätze mit diesen Tests marginal\", so eine Sprecherin. Die Phantasie liege vielmehr in der regelmäßigen und langfristigen Anwendung von Vogelgrippe-Tests. Sofern Nutzgeflügel eines Tages systematisch gegen die Grippeviren untersucht werden sollte, rechnet sich Qiagen gute Chancen aus, \"signifikante Umsätze\" zu erwirtschaften. \"Wir bieten in diesem Bereich das breiteste Portfolio an\", so die Sprecherin. Neben den eigentlichen Tests habe Qiagen auch Test- und Probenvorbereitungen sowie Reagenzien im Portfolio.

Eine Spekulation auf Umsätze mit der Vogelgrippe stellt die Aktie von Biocryst Pharmaceuticals dar. Das US-Unternehmen verfügt über das Grippemedikament Peramivir, das derzeit auf seine Wirksamkeit gegen die Vogelgrippe getestet wird. Im Januar hat die Firma von der US-Arzneimittelbehörde FDA den beschleunigten Fast-Track-Status für die klinischen Versuche erhalten. Doch Vorsicht: 2002 ist Biocryst mit demselben Medikament in den klinischen Studien der Phase III durchgefallen. Dabei hatte sich herausgestellt, daß durch die Einnahme der Tabletten nicht genug Wirkstoff in den Patienten gelangte. Entwicklungspartner Johnson & Johnson kündigte daraufhin die Zusammenarbeit mit Biocryst, die Firma stellte die Entwicklung ein, die Aktie stürzte ab. Mittlerweile bietet Biocryst Peramivir als Injektion an. Dadurch soll gewährleistet werden, daß genug Wirkstoff in den Körper gelangt. Das scheint auch die Phantasie der Aktionäre anzuregen. Seit den Tiefstständen bei drei Euro im Mai vergangenen Jahres hat die Aktie ihren Wert versechsfacht. Noch eine Nummer spekulativer sind die Papiere der US-Firmen Avi Biopharma und Generex Biotech. Avi Biopharma sorgte mit Zwischenergebnissen des Mittels Neugene in der Fachwelt für Aufsehen. Tests haben ergeben, daß Neugene effektiv gegen verschiedene Grippestämme wirkt. Das Unternehmen hofft nun, diesen Effekt auch auf den Vogelgrippe-Erreger H5N1 übertragen zu können. Allerdings befindet sich das Produkt noch in einem recht frühen Entwicklungsstadium. Dennoch sind die Zocker längst aktiv: Avi Biopharma wird an den Börsen heiß gehandelt. Generex arbeitet seinerseits an einem Impfstoff, der die Wirkung anderer Grippe-Impfstoffe verstärkt. Wie der Avi-Biopharma-Kurs ist auch die Generex-Aktie explodiert. Die Gefahr ist groß, daß am Ende nur Rauch übrigbleibt.

Das ist im Fall Lanxess kaum zu befürchten. Neben der Weiterentwicklung von Preventol denkt Marktbereichsleiter Schlegel bereits an neue Herausforderungen: Desinfektionsmittel für den medizinischen Bereich zum Beispiel. Schlegel: \"In Krankenhäusern gibt es viele resistente Viren.\" Experten schätzen, daß daran jährlich 40000 Menschen sterben. Der Lanxess-Mann träumt von Desinfektionsmitteln, die diesen Viren den Garaus machen. \"Das trifft genau unsere Kernkompetenz\", schwelgt Schlegel. \"Damit würden wir unsere Position in der Champions League der Desinfektion weiter festigen.\"


Autor: SmartHouseMedia (© wallstreet:online AG / SmartHouse Media GmbH),09:12 05.03.2006

Habe bereits in einem anderen Thread ähnliches gepostet, allerdings ist es da leider zu keiner kostruktiven Diskussion gekommen.

Bei Recherchen zu Unternehmen, die von der Vogelgrippe profitiert haben, bin ich auf folgenden Artikel gestoßen:

www.faz.net/s/...9FB2EF9CA376CF4BC4~ATpl~Ecommon~Sspezial.html

Auch wenn diese Unternehmen zum Teil noch kein Medikament auf dem Markt haben und auch nicht sehr positiv dargestellt werden, so sind deren Aktien in Folge der Vogelgrippe doch enorm gestiegen (siehe Charts).

Da die Umsätze in D. zu normalen Zeiten leider sehr gering sind und man daher in einem falleden Markt Probleme bekommen wird, habe ich mich heute in den USA auf vier Unternehmen gestreut Anteile erworben.
Und zwar von AVI BIOPHARMA INC., BIOCRYST PHARMACEUTICALS INC., GENEREX BIOTECHNOL.CORP. sowie SINOVAC BIOTECH LTD..

Ich denke bei einer starken Ausbreitung der Grippe werden diese Aktien für einige Prozent gut sein. Allerdings rechne ich auch mit mind. 50% Verlust, falls ein anderes Szenario eintrifft.

Trotzdem wünsche ich natürlich nicht, dass es noch schlimmer kommt. Aber ich denke das sollte klar sein.

weisst du ob diese beiden unternehmen denn ein wirksames mittel haben gegen die schweine-grippe? bzw ob diese noch benötig werden? Roche hat ja schon einen Großaufrtrag für Tamiflu bekommen

habe es gestern genauso gemacht und mir mal alle "Vogelgrippe-Aktien" angeschaut.

Hier mal eine gute Aufstellung:

www.comdirect.de/forum/fdo/...eadID=45552&pager.offset=20

Als aussichtsreichensten erschienen mir im Hinblick auf Marktkapitalisierung, Assets (Cash), Umsätze usw. Biocryst und AVI Biopharm.

Habe heute zwei Order in den Markt gegeben, wobei ich bei Biocryst nur knapp das Limit verfehlt habe. Nun ja, bei AVI Biopharm hat es ja geklappt.

Ich sehe es genauso, wie Du, mit der zukünftigen Entwicklung der Aktien. Sollte sich die Schweinegrippe zu einer Pandemie entwickeln, wird die Aktie m.M. nach wie 2006 steigen. Wenn nicht, wird es schnell wieder in Richtung Süden gehen. Nur wollte ich diesmal mit dabei sein und mich nicht ärgern, wenn es doch wieder steil aufwärts geht. Warten wir es mal ab...

Die anderen von Dir genannten Unternehmen erachte ich nicht so aussichtsreich. Insbesondere Generex konnte mich im Hinblick auf die Kriterien nicht überzeugen.

weder AVI noch Biocryst haben meines Wissens bereits einen Grippeimpfstoff auf dem Markt. Bei beiden Unternehmen handelt es sich um Biotech-Firmen, die u.a. an Impfstoffen forschen.

Biocryst entwickelt das Medikament "Peramivir" und AVI Biopharm das Medikament "Neugene", welches gegen verschiedene Grippestämme wirkt.

Ein wirksames Mittel gegen Schweinegrippe gibt es m.W. nicht, ob ein solches benötigt wird, wird die nahe Zukunft zeigen. Wenn ja, geht es bei den vorgenannten Aktien wahrscheinlich deutlich aufwärts.

aber nur auf Englisch:

 "AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: third-generation NeuGene antisense drugs and cancer immunotherapy. AVI’s lead NeuGene antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI’s antiviral program uses NeuGene antisense compounds to target single-stranded RNA viruses, including West Nile virus, SARS coronavirus, calicivirus and hepatitis C. AVI’s second technology, Avicine®, is a therapeutic cancer vaccine with late-stage trials planned for the treatment of pancreatic cancer. More information about AVI is available on the company’s Web site at www.avibio.com/."

www.avibio.com/pr/pr227.php

Portland (aktiencheck.de AG) - Die amerikanische AVI BioPharma Inc. (ISIN US0023461041/ WKN 908085) hat vom amerikanischen Verteidigungsministerium drei Aufträge zur Entwicklung von Medikamenten gegen mögliche terroristische Angriffe mit Biowaffen erhalten. Wie der Konzern am Montag erklärte, beläuft sich das Gesamtvolumen der vom amerikanischen Department of Defense vergebenen Aufträge auf 7,1 Mio. Dollar. Im Rahmen der Vereinbarung wird AVI BioPharma, basierend auf seiner NEUGENE-Technologie, Medikamente gegen mögliche Angriffe mit Milzbrand-Erregern sowie Ebola-Viren und Marburg-Viren entwickeln.  (07.05.2007/ac/n/a)

Schweinegrippe

WHO verschärft Pandemie-Warnung auf Stufe vier

Nachdem die Schweinegrippe auch Europa erreicht hat reagiert die Weltgesundheitsorganisation (WHO). Sie setzt die Pandemie-Warnung eine Stufe nach oben. Bisher galt die Warnstufe drei. Stufe sechs würde einen weltweiten Ausbruch einer Krankheit bedeuten.

Nach Einschätzung der Weltgesundheitsorganisation hat sich Kreisen zufolge das Risiko für eine weltweite Ausbreitung der Schweinegrippe deutlich verschärft. Die UN-Organisation wolle ihre Pandemie-Warnung am Montagabend um einen Rang auf Stufe vier anheben, hieß es in Kreisen, die mit der mit Spannung erwarteten Entscheidung vertraut waren. Damit würde die Organisation vor einer um sich greifenden Übertragung unter Menschen warnen, die den Boden für einen Ausbruch innerhalb größerer Gemeinschaften bereite. Bisher galt die Warnstufe drei, mit der sporadische, voneinander unabhängige Fälle an verschiedenen Orten festgestellt werden. Die höchste Stufe sechs bedeutet den weltweiten Ausbruch einer Krankheit.

Die WHO hat die Definition ihrer Warnstufen kurz vor Bekanntgabe der Entscheidung geändert. Durch die Verschärfung treten weitere Vorsorge- und Koordinierungsmaßnahmen in Kraft.


Nach Fällen in Mexiko, den USA und Kanada hat die Schweinegrippe am Montag auch Europa erreicht. In Spanien und Großbritannien gibt es Infizierte. In Deutschland bestätigten sich dagegen mehrere Verdachtsfälle nicht. Das Auswärtige Amt und die EU-Kommission rieten von nicht zwingenden Reisen nach Mexiko ab.

gxb/Reuters

www.focus.de/panorama/welt/...g-auf-stufe-vier_aid_394000.html

In D. eröffnen avi & co ganz positiv. An welcher Börse hast du denn geordert?
Entscheidend für eine Kursexplosion wird wohl auch sein, wie lange der Virus braucht in größerem Maße gegen Tamiflu und das GSK resistent zu werden.

Dann könnte ich mir auch vorstellen, dass verstärkt Fördermittel in solche Unternehmen fließen.

Momentan kommt die Aktie in den Staaten trotz positiver Meldung heute etwas zurück. Ich werde erstmal drin bleiben!

Habe übrigens gestern in FFM gekauft.

In den USA gibt es übrigens sogar einen Index, in dem "Vogelgrippe- und Schweinegrippeaktien" zusammengefaßt sind.

www.quote.com/news/story.action?id=PRN118p6273

"The strength of AVI's PMO chemistry is evident in compounds such as AVI-6002, which is designed to provide a novel approach to the treatment of Ebola virus infection. Drug optimization required us not only to identify the most effective genes and sequences but also to develop oligomer chemistry to target genetically variable viral transcripts," said Leslie Hudson, Ph.D., President and Chief Executive Officer of AVI BioPharma. "These issued patents cover a key target of our compound and helps protect this novel mechanism of action. We believe the new chemistry could be highly applicable to viruses such as influenza and hepatitis C (HCV) whose error-prone replication leads to high rates of mutation and drug resistance."

Preclinical results of AVI-6002 demonstrate reproducible and high rates of survival in non-human primates challenged with a lethal infection of the Ebola Zaire virus. AVI has received clearance from the United States Food and Drug Administration (FDA) for the Investigational New Drug (IND) application filed for AVI-6002. This research was conducted in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), a co-assignee on the patents. The majority of the collaborative research effort between AVI and USAMRIID has been supported by a research contract from the Department of Defense's Transformational Medical Technologies Initiative with the goal of developing a new antiviral (antisense) platform targeting hemorrhagic fever viruses.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

AVI Press and Investor Contact:
Julie Rathbun
Investor Relations
(541) 224-2575
Investorrelations@avibio.com

Aber auch SARS musste erst noch mutieren, bis es wirklich gefährlich wurde.

"Präsident Barack Obama bat den Kongress um zusätzliche Mittel in Höhe von 1,5 Milliarden Dollar zur Bekämpfung der Krankheit. Das Geld werde beispielsweise für den Ausbau der Medikamentenvorräte, die Diagnose und die Entwicklung eines Impfstoffes benötigt, so ein Sprecher", das sind ja schon mal gute Neuigkeiten, aber zur Zeit wird halt wirklich deutlich, dass der Virus in der momentanen Form nicht gefählicher ist, als die normale Grippe.

mit 8k und bleibe notfalls auch LONG an Board wenns weiter nach unten geht.

 

Bin absolut von AVI überzeugt, die haben das US_Verteidigungsministerium im Rücken als Geldgeber. Hier ist einiges möglich und irgendwann kommt ne super NEWS und wir stehen RUCK ZUCK wieder bei 8$!!

Wenn sich die Schweinegrippe zu einer Pandemie entwickelt, der Virus sogar noch resistent gegen Tamiflu wird und in der Welt eine Panik hervorgerufen wird, sollte sich der Aktienkurs schnell vervielfachen. Dann vielleicht noch eine passende Firmenmeldung...

Viele "wenn`s", aber ich bleibe dabei und lehne mich zurück. Solange die Schweinegrippe akut ist, verkaufe ich keine Aktie.

Kam gerade in den Tagesthemen im ZDF, dass die WHO die Pandemie-Warnstufe auf 2 (zweithöchste) erhöht hat.

WHO - Zweithöchste Stufe 5 erreicht
29. April 2009, 22:13
--------------------------------------------------

Weltweite Ausbreitung der Schweinegrippe könnte unmittelbar bevor stehen
Genf - Die Weltgesundheitsorganisation (WHO) hat wegen der sich ausbreitenden Schweinegrippe das Pandemie-Risiko auf die zweithöchste Stufe 5 angehoben. Das teilte WHO-Generaldirektorin Margaret Chan am Mittwochabend vor Journalisten in Genf mit. Die weltweite Ausbreitung des mutierten Schweinegrippevirus H1N1 könnte unmittelbar bevorstehen. Gleichzeitig sagte Chan aber auch, noch nie in der Geschichte sei die Welt so gut auf eine Grippe-Pandemie vorbereitet gewesen. Die Regierungen sollten ihre Vorsorgepläne aktivieren und in Alarmbereitschaft bleiben.

Es war bereits die zweite Verschärfung seit Anfang der Woche. Bei Stufe 5 geht die WHO davon aus, dass die meisten Länder in diesem Stadium noch nicht betroffen sind. "Die Ausrufung der Phase 5 ist aber ein starkes Signal, dass eine Pandemie bevorsteht und die Zeit für einen Abschluss der Organisation und Umsetzung der geplanten Schutzmaßnahmen kurz ist", heißt es in den Erläuterungen. (APA/dpa/Reuters)

If AVI can secure this contract, which is expected to be awarded later this year, possibly as soon as the summer, it would bring in a total of $50 million, Hudson says. This would be a significant boon to the company, which had $11.5 million in cash entering 2009 year and raised another $16.5 million from Eastbourne Capital and other institutional investors in late January.

“Thus far, we have the only therapeutic approach with sufficient data to be allowed into man,” Hudson says.

As a reminder, AVI got to this point after showing that 100 percent of monkeys who were exposed to Ebola or Marburg lived if they were taking the company’s experimental drugs, AVI-6002 and AVI-6003, respectively.

Of course, that’s a really compelling way to design an experiment, but not ethical to do in people. So what AVI needs to do in a clinical trial is just give healthy volunteers the drug and see if it’s safe, without exposing anybody to Ebola or Marburg. The combination of effectiveness in animals and a pair of safety studies in humans could lead the federal government to purchase bulk stockpiles of the drug for use in case of a scare, Hudson says. He didn’t say how long it would take to get enough convincing data for the Department of Defense to buy a stockpile.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com or call 206-624-2374.

 

Das heißt hier ist nicht nur ein kurzer Zock möglich sondern auch ein LONG-Investment lohnenswert! Ich verkaufe meine 8k nicht für unter 3€!!

Also die Beurteilung der aktuellen Lage durch die WHO anhand von Stufen ist in etwa genauso brisant wie die Wirtschaftsprognosen der Bundesregierung.

Ist natürlich trotzdem positiv zu werten.

gehts neu los...

 

so rebound setzt ein!!!

Tiefkurs 0,72$ das GAP ist nun zu und es kann aufwärts gehen!

Aktuell schon wieder bei 0,78$!! img.wallstreet-online.de/smilies/eek.gif" style="max-width:560px" alt="aufmerksam" title="aufmerksam" />  img.wallstreet-online.de/smilies/eek.gif" style="max-width:560px" alt="aufmerksam" title="aufmerksam" />      
 

... wirklich keine schöne Kursentwicklung in den letzten Tagen...

Egal, ich bleibe erstmal dabei!

auch keiner mehr raus...meine 8k gebe ich erst zu 3€ ab.

 

Also spätestens dann wenn der Vertrag unterzeichnet ist, also in ca. 1 Monat:-)

das mit dem Vertrag mal bitte erläutern!

Die Kursentwicklung einiger Biotechaktien in den letzten Tagen finde ich wirklich sehr positiv. Ich sehe da durchaus einen Aufwärtstrend. Dieser mag zwar durchaus eher durch den allgemeinen Aufwind an der Finanzmärkten, als durch die Schweinegrippe getragen werden, aber ich denke das ist zu verkraften.

Ich denke zur Schweinegrippe ist zu sagen, dass ohne eine Mutation des Virus wahrscheinlich nicht mehr all zu viel zu holen ist. Und da sich die Grippesaison dem Ende neigt, wird wohl vor allem der nächste Herbst wieder spannend werden. Denn wir wissen ja, dass es auch bei der Spanischen- und der Vogelgrippe ein bis zwei Jahre gedauert hat.

www.tagesschau.de/multimedia/audio/audio38104.html  -  Interessant, aber inhaltlich nicht unbedingt  besser als Panikmeldungen.

General and Administrative (G&A) expenses for the first quarter of 2009 decreased to $2.2 million from $2.6 million for the first quarter of 2008, due primarily to one-time non-cash stock compensation expenses incurred in the prior-year quarter related to the Ercole acquisition. Net interest income declined in relation to declines in market rates of interest on the Company's interest-earning investments.

The gain on warrant liability of $2.6 million was the result of the decline in the Company's stock price subsequent to the issuance of warrants as a part of the private equity financing that closed in January 2009. In general, the gain or (loss) on warrant liability contribution to the company's financial statement fluctuates with the price of the Company's stock.

AVI had cash, cash equivalents and short-term securities of $25.0 million as of March 31, 2009, an increase of $13.5 million from December 31, 2008. This increase was due primarily to the private equity financing that raised net proceeds of $15.5 million, partially offset by cash used in operations of $1.6 million and property and equipment and patent-related costs of approximately $300,000.

"AVI has advanced each of its lead drug candidates in Duchenne muscular dystrophy (DMD) and Ebola and Marburg virus infections," said Leslie Hudson, Ph.D., President and Chief Executive Officer of AVI BioPharma, "We now have four drug candidates in, or approved by the FDA for, the clinic and two lead compounds in preclinical development, one for Junín virus and a second DMD candidate based on our novel PPMO chemistry."

First Quarter and Recent Corporate Highlights


--  Announced a $2.5 million contract with Children's National Medical
   Center in Washington, D.C. to support preclinical studies in the
   development of AVI-4658 for treatment of Duchenne muscular dystrophy. The
   work will be conducted with Children's National collaborators Eric Hoffman,
   Ph.D., an authority on DMD and Professor of Pediatrics, and Edward Connor,
   M.D., Director, Office of Investigational Therapeutics and Professor of
   Pediatrics.  The collaboration will support the series of GLP toxicology
   studies for AVI-4658 which is required to release the clinical hold on the
   US IND.
--  Received key patents for drug candidate AVI-6002 targeting Ebola Zaire
   Virus protein VP35.The patents cover composition and methods to target the
   Ebola virus VP35 protein with a range of PMOplus(TM) compounds.
--  Announced treatment of the first patient in a clinical trial
   evaluating IV delivery of AVI-4658 for the treatment of Duchenne muscular
   dystrophy (DMD). The open label trial is evaluating multiple infusions over
   12 weeks of ascending doses of AVI-4658 and includes measures of safety,
   efficacy and pharmacokinetics.
--  Announced successful completion of a single injection, dose escalation
   Phase 1 trial of AVI-4658 for the treatment of DMD by exon skipping. AVI-
   4658 induced a robust expression of dystrophin following IM injection in a
   series of drug-treated patients such that up to 80 of fibers were positive
   for dystrophin expression, when one corrects for background expression in
   the other, saline-treated foot.  Equally importantly, individual fibers
   showed new protein expression at a level up to 40% of normal.  There was no
   immune response to the protein and no serious, treatment-related side
   effects were observed.
--  Announced publication of pre-clinical results in Proceedings of the
   National Academy of Sciences (Saovaros Svasti et al (January 12, 2009)
   Proc. Natl Acad. Sci. USA, 10.1073/PNAS 0812436106) demonstrating the
   effectiveness of a systemically delivered PPMO-based splice switching
   oligomer or SSO  in vivo in a mouse model of an inherited blood disorder.
--  Announced the appointment of Stephen B. Shrewsbury, M.D., as Chief
   Medical Officer and Senior Vice President of Clinical and Regulatory
   Affairs.
--  Announced the retirement of John Fara, PhD., and the appointment of
   Christopher S. Henney, Ph.D., D. Sc. and M. Kathleen Behrens, Ph.D. to the
   Company's Board of Directors.
   
Guidance:

For 2009, AVI confirms its guidance for expenditures for operations, net of government funding and other collaborative efforts, to be approximately $10 to $12 million. The Company believes it will be awarded certain government contracts to pursue the continued development of its antiviral compounds and has assumed a revenue contribution from these awards in providing this guidance. Should the Company not receive the additional contracts, or should their timing be delayed, they may have a negative impact on these projections.

Conference Call

AVI management will hold a conference call to report first quarter 2009 financial results on Monday, May 11, 2009, at 9:30 a.m. Eastern time (6:30 a.m. Pacific time).

Individuals interested in listening to the live conference call may do so by dialing 877-723-9519 toll free within the United States and Canada, or 719-325-4809 for international callers.

A replay of the call will be available by dialing 888-203-1112 toll free within the U.S. and Canada, or 719-457-0820. The passcode for the replay is 5077924. In addition, a recording of the call will be available within approximately 24 hours at www.avibio.com.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.


                        AVI BIOPHARMA, INC.
                 (A Development-Stage Company)

                   STATEMENTS OF OPERATIONS
                         (unaudited)
            (in thousands, except per share amounts)


                                            Three Months Ended
                                                 March 31,
                                 ----------------------------------------
                                         2009                 2008
                                 -------------------  -------------------
Revenues, from license fees,
grants and research contracts    $             3,150  $             5,625

Operating expenses:
 Research and development (1)                  4,495                6,903
 General and administrative (1)                2,220                2,553
 Acquired in-process
   Research and development                        -                9,916
                                 -------------------  -------------------
                                               6,715               19,372

Other income (loss):
   Interest income, net                           16                  167
   Gain (loss) on warrant
    liability                                  2,622               (1,435)
                                 -------------------  -------------------

Net loss                          $              (927) $           (15,015)
                                 ===================  ===================
Net loss per share -- basic and
diluted                          $             (0.01) $             (0.23)
                                 ===================  ===================
Shares used in per share
calculations                                  80,759               65,188
                                 ===================  ===================

(1) Certain prior year amounts have been reclassified to conform to current
   year presentation. These changes did not have a significant impact on
   Company’s net loss, assets, liabilities, shareholders’ equity or cash
   flows.



                    BALANCE SHEET HIGHLIGHTS
                          (unaudited)
                        (in thousands)

                                       March 31,           Decmeber 31,
                                         2009                  2008
                                 -------------------  -------------------

Cash, cash equivalents and
short-term securities            $            25,008  $            11,474
Total current assets                           28,779               17,044
Total assets                                   37,017               25,536
Total current liabilities                      11,616                7,288
Total shareholders’ equity        $            22,890  $            15,732

AVI Press and Investor Contact:
Julie Rathbun
Investor Relations
(541) 224-2575
Investorrelations@avibio.com

www.quote.com/news/story.action?id=INW131u3561

ein klassischer "sell on good news" weil alles eingepreist war?

 

wie geht es wohl weiter mit diesere firma?

Auch heute wieder ein kleines Plus an der NASDAQ.

......einer der vielen von Fortunatus, gelle 1?

deshalb hast Du ihn ja auch schon vielfach positiv bewertet...   lol

Du scheinst wirklich sehr vergesslich zu sein!

Die Entwicklung ist ja durchaus erfreulich, allerdigs gibt mir der Wechselkursverlust zu denken.

Meint ihr da sollte man sich mit einem Derivat absichern?

Wenn Du keine 10k oder mehr an Euro oder Dollar in AVI investiert hast, würde ich die Gewinne einfach weiter laufen lassen ohne eine Absicherung durch ein Derivat.

Könnte mir gut vorstellen, dass die Aktie nach einer positiven Meldung zu einem in Entwicklung befindlichen Medikament mal schnell einen Satz von 100% und mehr macht...

denke ich auch...hier ist noch einiges zu erwarten.

 

denke außerdem dass es auch ohne weitere (große) news relativ schnell Richtung 1,50$ gehen wird!!

stämmt sich die Aktie und legt zur Zeit nachrichtenlos unter relativ hohem Volumen 16 Prozent zu!

Dabei bleiben und auf den richtigen Move warten!

null

Item 1.01.  Entry into a Material Definitive Agreement.

 

On May 28, 2009, AVI BioPharma, Inc. (the “Company”) entered into a contract amendment to its contract HDTRA 1-07-C-0010 with the U.S. Defense Threat Reduction Agency (“DTRA”) to support additional tasks for the continued development of DTRA’s programs with the Transformational Medical Technologies Initiative (“TMTI”) for the Company’s Ebola Virus and Marburg Virus therapeutic product candidates.  Under this amendment, DTRA has extended the contract performance period to November 29, 2009 and added a cost modification of an additional $5.9 million, thus increasing the contract amount to $33.9 million.  The Company may spend up to 50% of the additional contract amount without further approval but authority to spend up to the full additional amount must be subsequently granted, by DTRA, which is expected to be completed on or before June 30, 2009.

secfilings.nasdaq.com/...DK&RcvdDate=6%2F2%2F2009&pdf=

heute auch eingestiegen.

AVI has selected and begun preclinical development on a lead molecule, based on AVI's proprietary PPMO chemistry, that has the potential to skip dystrophin exon 50 and so not only restore the proper RNA reading frame but also produce functional dystrophin in patients with certain types of mutation. This therapeutic approach is similar to that of AVI-4658, which AVI has in more advanced development to potentially treat DMD patients with mutations that could benefit from skipping exon 51 of the dystrophin gene.

About Duchenne Muscular Dystrophy (DMD)

DMD is the most common fatal genetic disorder to affect children around the world. Approximately one in every 3,500 boys worldwide is afflicted with Duchenne muscular dystrophy with 20,000 new cases reported each year. It is a devastating and incurable muscle-wasting disease associated with specific inborn errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Symptoms usually appear in male children before age six. Progressive muscle weakness of the legs and pelvis eventually spreads to the arms, neck, and other areas. By age 10, braces may be required for walking, and most patients are confined to a wheelchair by age 12. Eventually, this progresses to complete paralysis and increasing difficulty in breathing. The condition is terminal and death usually occurs before the age of 30. The outpatient cost of care for a non-ambulatory DMD boy is among the highest of any disease. There is currently no cure for DMD, but for the first time in decades, there are promising therapies in or moving into development.

About Charley's Fund Inc.

Charley's Fund Inc. is a not-for-profit foundation that finances therapeutics development for Duchenne muscular dystrophy. The foundation's mission is to expedite a treatment or cure in time to help this generation of children who suffer from DMD. Charley's Fund Inc. targets translational research -- research that moves science from the lab into human clinical trials. The 501 (c)(3) public charity was co-founded in 2004 by Benjamin Seckler, M.D. and Tracy Kramer Seckler, whose son Charley has Duchenne muscular dystrophy. To learn more about Charley's Fund Inc., visit www.charleysfund.org.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

AVI Press and Investor Contact:
Julie Rathbun
Investor Relations
(541) 224-2575
Investorrelations@avibio.com

Charley's Fund Inc. Contact:
Tracy Seckler
(413) 528-5744
info@charleysfund.org

www.quote.com/news/story.action?id=INW155u4544

Biotech scheint gerade wirklich gut zu laufen. Generex, ein anderer potenzieller Schweinegrippeprofiteur in meinem Depot, ist gestern in usa um fast 80% gestiegen.

Wie ist denn eure strategische Ausrichtung?
Meint sollte mit einem engen Stopp arbeiten oder eher nur den Einstandskurs sichern und langfristiges Potenzial ausschöpfen?

... von knapp 2 Prozent.  :-)

www.avibio.com/annual_report.php

Auf Grund der teilweise hohen täglichen Schwankungsbreite halte ich enge Stopps bei der Aktie für ungeeignet. Ein Investment in diese Aktie ist relativ hoch spekulativ. Dessen sollte man sich bewusst sein.

Ich bleibe erstmal - ohne jegliche Stopps - dabei und warte auf einen richtigen Move von 80% und höher. Sollte dieser eintreten, würde ich erstmal meine Gewinne mitnehmen.

Mehr als 70 Fälle von Schweinegrippe bestätigt


Die Schweinegrippe wird hierzulande nicht mehr ganz ernst genommen

08. Juni 2009

In Deutschland gibt es 19 weitere Fälle der Schweinegrippe. Wie das Robert-Koch-Institut (RKI) am Montag in Berlin mitteilte, wurden 14 davon aus den Vereinigten Staaten eingeschleppt. Je ein Betroffener kam aus Kanada, Argentinien und Panama, zwei Menschen steckten sich in Deutschland bei erkrankten Reisenden an. Damit stieg die Zahl der Schweinegrippefälle in Deutschland auf insgesamt 68. Die ersten Schweinegrippefälle waren in Deutschland Ende April bestätigt worden. In der Regel verliefen die Erkrankungen hierzulande mild.

In Bayern wurden vier neue Erkrankungen diagnostiziert, wie das Landesamt für Gesundheit am Montag in Würzburg mitteilte. Auch in Baden-Württemberg und in Sachsen wurden je ein neuer Fall gemeldet.

Im unterfränkischen Landkreis Würzburg sind dem Amt zufolge drei 16-Jährige und ein 17-jähriges Mädchen betroffen. Sie hatten sich offenbar auf einer Party angesteckt. Die vier Jugendlichen befinden sich derzeit vorsorglich in häuslicher Isolierung. Die Feier wurde auch von einer infizierten Jugendlichen besucht, die zuvor aus Argentinien zurückgekehrt war.

Gesundheitsrisiko Amerika-Reise

Nach Angaben des Landesgesundheitsministeriums in Stuttgart steckte sich ein 29-jähriger Mann aus dem Rhein-Neckar-Kreis bei einer Frau an. Die 28-Jährige war kurz zuvor von einer Reise in die Vereinigten Staaten zurückgekehrt, wo sie sich offenbar mit dem Virus infiziert hatte.

In Sachsen ist eine Studentin aus Dresden erkrankt, wie das Gesundheitsministerium mitteilte. Sie war am vergangenen Donnerstag aus New York zurückgekehrt.

Nach Angaben des Robert-Koch-Instituts wurden mit 44 Fällen die meisten Infektionen aus den Vereinigten Staaten eingeschleppt. Nach den jüngsten Angaben der Weltgesundheitsorganisation (WHO) meldeten 73 Länder insgesamt rund 25.300 Fälle sowie 139 Tote.

www.faz.net/s/...4E6~ATpl~Ecommon~Scontent.html?rss_googlefeed

...kurz vor Handelsschluss ins Plus gedreht und auf Tageshoch geschlossen!

Könnte möglicherweise etwas im Busch sein...

secfilings.nasdaq.com/...DK&RcvdDate=6%2F8%2F2009&pdf=

Mit der Anhebung auf Stufe 6 stellt die WHO die weltweite Ausbreitung des Erregers fest. Die höhere Pandemie-Warnstufe bedeutet nicht, dass das Virus gefährlicher geworden ist und mehr Todesfälle auftreten. Die meisten Erkrankungen der Schweinegrippe verlaufen mild, brauchen keine Behandlung und sind nicht tödlich. "Phase 6 hat keine Bedeutung hinsichtlich der Schwere der Krankheit. Sie ist nur bedeutend für die geographfische Ausbreitung", sagte WHO-Sprecher Gregory Hartl. "Tatsächlich haben wir es bisher mit einer milden Erkrankung zu tun", so Hartl. Die Ansteckungszahlen seien zwar hoch, aber der Großteil der Fälle verlaufe harmlos und brauche keine Behandlung. Die Feststellung der Pandemie durch die WHO soll die Produktion von Grippemedikamenten beschleunigen, zudem sollen sich die Regierungen nun verstärkt um eine Eindämmung der Epidemie bemühen.

Das H1N1-Virus ist zur Zeit zwar hoch infektiös, aber relativ harmlos. In einer ersten im Fachmagazin " Science" veröffentlichten Analyse hatten Wissenschaftler damit gerechnet, dass sich das Virus weltweit ausbreiten würde. Die Forscher kamen darin zu dem Ergebnis, dass der aktuelle Influenza-Erreger H1N1 ansteckender ist als die normale, saisonale Grippe. Etwa 0,4 bis 1,4 Prozent der Infizierten sterben an der Schweinegrippe. Das Virus scheine in etwa genauso gefährlich zu sein wie die H1N1-Variante von 1957. Damit - und das ist die gute Nachricht - wäre es deutlich weniger aggressiv als die Spanische Grippe von 1918/19. Ihr fielen schätzungsweise 40 bis 50 Millionen Menschen zum Opfer.

Bislang weltweit 141 Tote

Laut WHO-Angaben vom Mittwoch haben 74 Länder insgesamt 27.737 bestätigte Fälle von Schweinegrippe gemeldet - die Dunkelziffer beträgt laut Experteneinschätzung wahrscheinlich mehrere hunderttausend, da die meisten Infektionen so mild verlaufen, dass sie nicht registriert werden. Mehr als die Hälfte der bestätigten Fälle hat alleine die USA gemeldet. 141 Menschen sind weltweit an der Krankheit gestorben, davon 106 in Mexiko und 27 in den USA. Zum Vergleich: An normaler Grippe sterben Schätzungen zufolge jährlich weltweit rund 500.000 Menschen.


Beunruhigend war für Experten jedoch, dass unter den 141 Todesopfern viele junge und gesunde Menschen waren - die sonst kaum einer normalen Grippe zum Opfer fallen würden. Zudem hat sich die Verbreitung des Virus mit dem Beginn des Sommers in der nördlichen Halbkugel entgegen einem normalen Grippevirus kaum verlangsamt. Experten geben daher keine Entwarnung: Es kann nicht ausgeschlossen werden, dass das Virus noch in eine gefährlichere Form mutieren wird - vor allem in einer zweiten Welle.

Auch in Deutschland kam es zu Ausbrüchen: In einer japanischen Schule in Düsseldorf haben sich mindestens 30 Schüler angesteckt. In Köln und München traten ebenfalls neue Schweinegrippe-Erkrankungen auf. Bundesweit gibt es 95 bestätigte Fälle.

Die WHO hatte am Donnerstag zu einer Dringlichkeitssitzung einberufen. Die eingeladenen Wissenschaftler hatten darüber beraten, ob für die aktuelle Ausbreitung der Schweinegrippe Pandemie-Alarm gegeben werden sollte oder nicht. Die WHO wollte sichergehen, dass die Länder entsprechend vorbereitet waren, damit eine weltweite Panik vermieden wird.

Nationaler Pandemieplan gibt die Richtung vor

Trotz der Hochstufung der Schweinegrippe zu einer Pandemie wird sich in Deutschland nach Auskunft des Robert-Koch-Instituts (RKI) zunächst nichts Wesentliches ändern. In Deutschland gebe es bereits jetzt die von der WHO in der höchsten Pandemie-Alarmphase 6 geforderten Strukturen und Expertengespräche, sagte RKI-Sprecherin Susanne Glasmacher in Berlin. Auch Bund und Länder stimmten sich bereits regelmäßig ab.

Das Pandemie-Warnsystem der WHO umfasst sechs Stufen: In den ersten drei dominieren Infektionen unter Tieren, nur wenige Menschen sind betroffen. In Stufe 4 kommt es zu "anhaltender Übertragung von Mensch zu Mensch", wie die WHO auf ihrer Website erläutert. Stufen 5 und 6 sind durch "weitverbreitete menschliche Infektionen" gekennzeichnet.


Stufe 1: Keine neuen Influenza-Viren-Subtypen bei Menschen. Es können Viren unter Tieren kursieren, das Ansteckungsrisiko für Menschen ist aber gering.

Stufe 2: Wie in Stufe 1, allerdings besteht ein substantielles Risiko, dass Menschen erkranken.

Stufe 3: Die Alarmphase beginnt. Einzelne Menschen infizieren sich mit dem neuen Virus-Subtyp. Übertragungen von Mensch zu Mensch gibt es keine oder nur selten im Falle engen Kontakts.

Stufe 4: Vereinzelt wird das Virus von Mensch zu Mensch übertragen. Die Infektionen sind örtlich begrenzt, was den Schluss erlaubt, dass das Virus nicht gut auf den Wirt Mensch angepasst ist.

Stufe 5: Infektionen häufen sich. Übertragungen von Mensch zu Mensch bleiben jedoch örtlich begrenzt. Das Virus passt sich immer besser an den Menschen an, es besteht ein großes Pandemie-Risiko.

Stufe 6: Die Pandemiephase. Infektionen nehmen weiter zu, die gesamte Bevölkerung ist betroffen.

Die Erhöhung der Pandemiestufe auf 6 wird dazu führen, dass die einzelnen Länder ihre eigenen Alarmstufen anpassen und getreu ihren Pandemieplänen Maßnahmen einleiten werden. Auch Deutschland hat einen Nationalen Pandemieplan, der im Falle einer ausbrechenden Seuche regelt, was zu tun ist. Nur: Seine Umsetzung ist Aufgabe der Länder, denn Gesundheit und Katastrophenschutz fallen nicht in die Kompetenz des Bundes. So haben die einzelnen Bundesländer ihre eigenen Pandemiepläne entwickelt. Droht da möglicherweise Kompetenzgerangel im Katastrophenfall? Das Bundesgesundheitsministerium bestreitet dies und verweist auf den Nationalen Pandemieplan, in dem die Verteilung der Bund-Länder-Kompetenzen geregelt ist. Und zwar so:


Laut Nationalem Pandemieplan soll eine Interministerielle Koordinierungsgruppe (mit der Abkürzung IntMinKoGr) die entscheidende Nahtstelle zwischen Bund und Ländern sein. "Mitglieder der IntMinKoGr sind Vertreterinnen und Vertreter der zuständigen Bundesressorts und der betroffenen Länder", heißt es in dem Papier.


Ab Risikophase 4 wird ein interner Krisenstab im Bundesgesundheitsministerium (BMG) einberufen. "Auf Bundesebene bereitet der Krisenstab [im BMG, Anm. d. Red.] gesundheitsbezogene Lösungsstrategien vor und bringt diese in den Gemeinsamen Krisenstab des BMI und des BMG oder die Interministerielle Koordinierungsgruppe ein."

Ein zweiter Krisenstab ist vorgesehen: der Gemeinsame Krisenstab der Bundesministerien für Inneres (BMI) und für Gesundheit. Seine Aufgabe im Behördendeutsch: "Dieser Krisenstab hält Kontakt zu den Krisenstäben der anderen Ressorts und der Länder und dient insbesondere der bereichsübergreifenden Abstimmung zeitkritischer Entscheidungen und Maßnahmen sowie der Risikokommunikation."


Fachlich beraten wird der Krisenstab vom Robert-Koch-Institut, dem Paul-Ehrlich-Institut und dem Bundesinstitut für Arzneimittel und Medizinprodukte.

Der zweite Krisenstab wurde bisher nicht einberufen. Dieser würde erst aktiv, wenn zum Beispiel öffentliche Großveranstaltungen untersagt werden müssten. Dafür gab es aber bisher keinen Anlass.

Mehrere Pharmakonzerne arbeiten bereits an einem Impfstoff gegen die Schweinegrippe. Bis zur Fertigstellung können allerdings bis zu sechs Monate vergehen. Die WHO sorgt sich auch schon um mögliche Verteilungskämpfe bei der Impfstoffverteilung. Weil reiche Länder, darunter Frankreich und Deutschland, bereits Verträge mit den Impfstoffherstellern abgeschlossen haben, könnten Entwicklungsländer nicht ausreichend mit Impfstoff versorgt werden. Die WHO geht davon aus, dass binnen eines Jahres höchstens 4,9 Milliarden Impfdosen hergestellt werden können. Das würde nicht für alle 6,8 Milliarden Menschen auf der Erde reichen, zumal jeder in der Regel zweimal geimpft werden muss. Ein weiteres Problem: Um die benötigten Mengen an Impfstoff gegen Schweinegrippe herzustellen, müssten die Hersteller die Produktion von Medikamenten gegen normale Grippe stoppen. Eine schwierige Abwägung, denn auch dadurch könnten Menschen gefährdet werden.

Im letzten Jahrhundert gab es drei Pandemien:


Zwischen 1918 und 1919 erkrankte ein großer Teil der Weltbevölkerung an der Spanischen Grippe. Nach WHO-Schätzungen fielen der Krankheit 40 bis 50 Millionen Menschen zum Opfer. Sie breitete sich damals in nahezu jeden Winkel der Erde aus und erreichte auch die Arktis und die abgelegenen pazifischen Inseln. An ihr werden alle nachkommenden Grippe-Epidemien gemessen.

Zwischen 1957 und 1958 grassierte die Asiatische Grippe. Etwa vier Millionen Menschen starben daran. Sie hatte ihren Ursprung in Südchina und breitete sich nach Singapur, Hongkong und in die USA aus.
An der sogenannten Hongkong-Grippe starben weltweit etwa zwei Millionen Menschen. Sie wurde Anfang 1968 in Hongkong entdeckt und griff auf die USA über. Ihren Höhepunkt erreichte die Grippewelle Ende 1968.

www.spiegel.de/wissenschaft/mensch/0,1518,629872,00.html

Deshalb befinde sie sich auch nicht in der Klinik, sondern sei zusammen mit ihrem Lebensgefährten in der gemeinsamen Wohnung unter Quarantäne. Die Infektionsschutzbeauftragte Berlins, Marlen Suckau, riet der Bevölkerung zur Anschaffung eines Mundschutzes: "Jetzt ist ein guter Zeitpunkt, sich einen zu kaufen." Sie wies darauf hin, dass die Stadt auf eine mögliche Ausbreitung der Grippe gut vorbereitet sei.

In Düsseldorf stieg die Zahl registrierter Fälle derweil nach Angaben der Stadt auf 82. Unter den Neuinfizierten sind eine 24-Jährige, die aus New York zurückkehrte, und ein 29-Jähriger, der in Amsterdam war. In Brandenburg wurde die Erkrankung bei einem 33-Jährigen bestätigt, der von einer USA-Reise zurückgekehrt war. Auch in Niedersachsen wurde ein weiterer Fall registriert: Die Zehnjährige aus Hannover hatte sich bei ihrer Mutter angesteckt.

dpa

Ich bin zu 1,45$ zwischenzeitlich ausgestiegen. Der Gane Sektor ist, wie der allg. Markt, sehr schwach.

Einzig Sinovac, ein Unternehmen, dass mit der chin. Regierung zusammenarbeitet, performt noch sehr stark. Ich glaub da hatte der Aktionär auch mal was drüber geschrieben.

Ich warte jetzt erstmal auf etwas günstigere Kurse.

aber bis jetzt keine News .

... dabei bleiben!

was für ein herrlicher Motag :-)

www.marketwire.com/press-release/...c-NASDAQ-AVII-1006881.html


AVI BioPharma Under Contract With U.S. Defense Threat Reduction Agency for Development of Therapeutics Targeting H1N1 Swine Flu

PORTLAND, OR--(Marketwire - June 22, 2009) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, is under contract with the U.S. Defense Threat Reduction Agency (DTRA) for development of one or more nucleotide-based candidate drugs targeting the present epidemic of H1N1 swine flu.

The material terms of this contract were previously announced by AVI on May 5, 2009 in a regulatory filing (8-K) with the U.S. Securities and Exchange Commission regarding a funding award of up to $5.1 million. The objective of the contract is to accomplish the preclinical development of one or more medical countermeasures based on AVI's proprietary antisense Phosphorodiamidate Morpholino Oligonucleotide (PMO) backbone and demonstrate efficacy using an appropriate animal model.

Under the contract, AVI will analyze the H1N1 sequence, determine appropriate targets and identify lead and back-up candidate drugs. The Company will also manufacture development grade material in sufficient quantities for planned animal tests and perform animal studies for lead and back-up candidate drugs.

Additional information regarding the DTRA contract can be found at: www.fbo.gov/download/cbb/...ef9/HDTRA1-09-C-0046_J&A_.pdf

About Defense Threat Reduction Agency

The Defense Threat Reduction Agency (DTRA) was founded in 1998 to integrate and focus the capabilities of the Department of Defense that address the weapons of mass destruction (WMD) threat. The mission of the DTRA is to safeguard America and its allies from WMD (e.g. chemical, biological, radiological, nuclear, and high yield explosives) by providing capabilities to reduce, eliminate, and counter the threat, and mitigate its effects. Under DTRA, Department of Defense resources, expertise and capabilities are combined to ensure the United States remains ready and able to address the present and future WMD threats. www.dtra.mil/index.cfm.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

www.avibio.com/pr/pr422.php

AVI BioPharma Under Contract with U.S. Defense Threat Reduction Agency for Development of Therapeutics Targeting H1N1 Swine Flu...

2$ sollten heute locker drin sein!!

AVI BioPharma Under Contract With U.S. Defense Threat Reduction Agency for Development of Therapeutics Targeting H1N1 Swine Flu



PORTLAND, OR -- (MARKET WIRE) -- 06/22/09 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, is under contract with the U.S. Defense Threat Reduction Agency (DTRA) for development of one or more nucleotide-based candidate drugs targeting the present epidemic of H1N1 swine flu.

The material terms of this contract were previously announced by AVI on May 5, 2009 in a regulatory filing (8-K) with the U.S. Securities and Exchange Commission regarding a funding award of up to $5.1 million. The objective of the contract is to accomplish the preclinical development of one or more medical countermeasures based on AVI's proprietary antisense Phosphorodiamidate Morpholino Oligonucleotide (PMO) backbone and demonstrate efficacy using an appropriate animal model.

Under the contract, AVI will analyze the H1N1 sequence, determine appropriate targets and identify lead and back-up candidate drugs. The Company will also manufacture development grade material in sufficient quantities for planned animal tests and perform animal studies for lead and back-up candidate drugs.

Additional information regarding the DTRA contract can be found at: www.fbo.gov/download/cbb/...ef9/HDTRA1-09-C-0046_J&A_.pdf

About Defense Threat Reduction Agency

The Defense Threat Reduction Agency (DTRA) was founded in 1998 to integrate and focus the capabilities of the Department of Defense that address the weapons of mass destruction (WMD) threat. The mission of the DTRA is to safeguard America and its allies from WMD (e.g. chemical, biological, radiological, nuclear, and high yield explosives) by providing capabilities to reduce, eliminate, and counter the threat, and mitigate its effects. Under DTRA, Department of Defense resources, expertise and capabilities are combined to ensure the United States remains ready and able to address the present and future WMD threats. www.dtra.mil/index.cfm.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

AVI Press and Investor Contact:
Julie Rathbuninvestorrelations@avibio.com
(541) 224-2575

erst ein Trade zu 1,97 Dollar.

www.themarketguardian.com/2009/06/...e-day-avi-biopharma-avii/

http://www.ariva.de/..._aufspringen_Global_Biotech_Investing_n3004716

AVI BioPharma signs agreement with US Defense Threat Reduction Agency for H1N1 Swine Flu therapeutics Deal In Brief
Monday June 22, 2009 14:46:35 EDT

http://www.quote.com/news/story.action?id=DTF173d7763

Heute gingen insgesamt über 10 Millionen Aktien über den Tresen und die Aktie schloss auf einem neuen Jahreshoch.

Global Biotech Investing - AVI BioPharma mit spek. Position aufspringen
09:35 23.06.09

Endingen (aktiencheck.de AG) - Die Experten von "Global Biotech Investing" raten bei der Aktie von AVI BioPharma (Profil) mit einer kleinen spekulativen Position aufzuspringen.

Das New Yorker AnaIystenhaus Maxim Group traue dem Papier ein Ziel von USD 3,50 zu! Das sei selbst nach der fantastischen Rally der letzten Wochen, in der sich der Anteilsschein bereits mehr als verdreifacht habe, ein weiteres Upside von satten 150%. AVI BioPharma sei ein Impfstoffforscher, der sich mittels seines auf der RNA- Technologieplattform basierenden Präparates Neugene einen Namen im Kampf gegen das Ebola-Virus gemacht habe. Tests hätten ergeben, dass der Wirkstoff effektiv gegen verschiedene Grippestämme eingesetzt werden könne. Die Hoffnungen lägen nun darin, dass das Unternehmen diesen Effekt auch auf das Schweinegrippe-Virus H1N1 übertragen könne. In Expertenkreisen würden der RNA-Technologie des Unternehmens bei einer möglichen Mutation des H1N1-Erregers die besten Chancen zugeschrieben.

In Regierungskreisen werde dies offensichtlich ähnlich gesehen und so habe AVI BioPharma bei seinen Forschungstätigkeiten zuletzt Unterstützung von höchster Ebene erhalten: Das US-Verteidigungsministerium habe dem Unternehmen drei Aufträge zur Entwicklung von Präparaten gegen mögliche terroristische Angriffe mit Biowaffen erteilt. Das Gesamtvolumen solle dabei rund USD 7 Mio. betragen.

Die Experten von "Global Biotech Investing" empfehlen bei der Aktie von AVI BioPharma mit einer kleinen spekulativen Position aufzuspringen und das gute Momentum mitzureiten. Das Investment sollte unbedingt mittels Stopp abgesichert werden. (Ausgabe 12 vom 22.06.2009) (23.06.2009/ac/a/a)

http://www.ariva.de/..._aufspringen_Global_Biotech_Investing_n3004716

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

AVI Press and Investor Contact:
Julie Rathbuninvestorrelations@avibio.com
(541) 224-2575

der Kurs fällt bei geringen Umsätzen. Ich habe noch einmal nachgekauft.

Tagestief mit 1,58 Dollar. Umsatz gering. Was läuft dort ?

noch einmal zu 1,60 Dollar nachgekauft. Ich glaube fest an eine gute Entwicklung.

www.stern.de/wissenschaft/medizin/...e-Wird-Zweite/705215.html

deutlich im PLus.

Schick mir bitte mal nen Link.

danke

Decon

www.nasdaq.com/aspxcontent/...px?selected=AVII&mkttype=pre

Wenn Du schon die vorbörslichen Kurse ansprichst dann sag auch das 8 einzelne 100ter Trades gelaufen sind mehr nicht.

Absolut keine Aussagekraft egal ob im Minus oder Plus Bereich.

Global Biotech Investing - AVI BioPharma spekulativ aufspringen
12:02 07.07.09

Endingen (aktiencheck.de AG) - Die Experten von "Global Biotech Investing" raten bei der Aktie von AVI BioPharma (Profil) mit einer kleinen spekulativen Position aufzuspringen.

Vor wenigen Tagen habe das Unternehmen einen Auftrag in Höhe von 5,1 Mio. USD von der US-Regierung erhalten. Bereits Anfang Mai sei mit der US-Defense-Threat-Reduction-Agency eine Vereinbarung zur Entwicklung mindestens eines Produktkandidaten gegen die Schweinegrippe getroffen worden. Nun sei dieser Deal endgültig fixiert worden.

Aktuell entwickle AVI BioPharma in Phase I die beiden Wirkstoffe AVI-6002 und AVI-6003 zur Behandlung von Ebola und des Marburg-Virus. Zusätzlich treibe das Unternehmen - teilweise auch in Zusammenarbeit mit Partnerunternehmen - Forschungsreihen im Bereich von Herz-/Kreislauferkrankungen und bei DMD, einer bislang tödlich verlaufenden Muskelerkrankung, voran. Diese Produktpipeline sei zwar spannend, da sich aber alles noch in einer frühen Forschungsphase befinde werde es noch Jahre dauern, bis das Unternehmen damit Geld verdiene. Deshalb seien unerwartete Aufträge wie aktuell seitens der US-Regierung ein Segen für AVI BioPharma. Eines sei sicher: Bringe das Unternehmen nur einen seiner Produktkandidaten zur Marktreife, würde dies einen Durchbruch für die nur USD 120 Mio. schwere Gesellschaft bedeuten.

Branchenexperten seien vom mittelfristigen Potenzial des Unternehmens komplett überzeugt. Neben dem Regierungsauftrag würden der Aktie derzeit auch durch die Aufnahme in den Russell 3000 Index Beine gemacht.

Die Experten von "Global Biotech Investing" empfehlen bei der Aktie von AVI BioPharma mit einer kleinen spekulativen Position auf die laufende Rally aufzuspringen. (Ausgabe 13 vom 06.07.2009) (07.07.2009/ac/a/a)


Offenlegung von möglichen Interessenskonflikten: Mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.

Quelle: Aktiencheck

heute und das Volumen hat auch angezogen. Keine News erkennbar.

Schweinegrippe USA planen Massenimpfung gegen Schweinegrippe-Virus

Im Kampf gegen die Schweinegrippe planen die USA im Herbst eine Massenimpfung. Die Gesundheitsbehörden wollen bis Mitte Oktober 100 Millionen Einheiten eines Impfstoffs zur Verfügung stellen.
Die Impfaktion soll sich auf Schulkinder, Schwangere sowie chronisch Kranke und Krankenhaus-Beschäftigte konzentrieren, die als besonders gefährdet durch das H1N1-Virus gelten.

Bisherigen Schätzungen zufolge sollen bereits eine Million Amerikaner an Schweinegrippe erkrankt sein – 170 starben, dies berichtete die „Washington Post“.

Bei der Weltgesundheitsorganisation (WHO) sind bislang rund 35 000 Erkrankungen in den USA registriert, Mediziner gehen aber weltweit von einer sehr großen Dunkelziffer aus. Experten warnten auf einem Gesundheitsgipfel vor der Einschätzung, dass die Pandemie bereits vorüber sei.

Vor einem Beginn der Massenimpfungen müsse aber zunächst garantiert werden, dass der Impfstoff sicher und effektiv sei – entsprechende Tests seien für August geplant, berichtete die „New York Times“. Da es aber vermutlich nicht genügend Impfstoff für die gesamte Bevölkerung gebe, müsse man sich zunächst auf Risikogruppen beschränken.

Die Bundesregierung will in der kommenden Woche festlegen, welche Bevölkerungsgruppen in Deutschland gegen die Schweinegrippegeimpft werden sollten.

„Wir müssen entscheiden, wer zu den Risikogruppen gehört“, sagte Bundesgesundheitsministerin Ulla Schmidt (SPD) dem Hörfunksender Hit-Radio Antenne Niedersachsen.

Dazu dürften die Beschäftigten im Gesundheitswesen, aber auch junge Menschen mit Grunderkrankungen gehören.

Für diese Gruppen solle eine Impfempfehlung ausgesprochen werden, so die Gesundheitsministerin.

Die Bestelloptionen für Grippemittel reichten aus, um jeden Deutschen zweimal zu impfen. Unklar sei noch, ob bei älteren Menschen eine Impfung sinnvoll sei, sagte Schmidt. In dieser Altersgruppe gebe es kaum Erkrankungen. Möglicherweise reiche hier der normale saisonale Grippeimpfstoff aus.

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA-based therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

AVI Press and Investor Contact:
Julie Rathbun
Investor Relations
(541) 224-2575
Investorrelations@avibio.com

und das Volumen stimmt auch.

neues 52 Wochen Hoch, gutes Volumen und die zwei Dollar werden gekratzt.

schöner Anstieg

The agreement has a one-year term, with an option to extend for additional years, and will provide approximately $1.2 million in support to AVI over the initial term for advancement of research, regulatory efforts and clinical trial recruitment.

AVI is currently conducting a dose-finding clinical trial evaluating the systemic delivery of AVI-4658. This is an open label, 12 week safety trial, which includes measures of drug efficacy and pharmacokinetics, being conducted in London, UK, at the UCL Institute of Child Health/Great Ormond Street Hospital NHS Trust facilities and at the Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK, which is the center for the European Treat Neuromuscular Diseases (Treat-NMD) initiative. The clinical costs for the trial are provided, in part, by the UK Medical Research Council.

AVI-4658 is designed to skip exon 51 of the dystrophin gene, allowing for restoration of the reading frame in the mRNA sequence. By skipping this exon, a truncated, yet potentially functional form of the dystrophin protein is produced, which could ameliorate the disease process and possibly prolong and improve the quality of life of these patients. Results from a Phase 1 proof-of-concept trial showed that injection of the drug into the muscles of a series of DMD boys successfully induced dystrophin production in a dose-responsive manner. Further, the drug was well tolerated, with no significant drug-related adverse events detected. The clinical trial was conducted in collaboration with the MDEX Consortium in London, UK. AVI is also developing AVI-5038, a new candidate drug based on second-generation PPMO chemistry and designed to skip exon 50. The preclinical work for AVI-5038 is funded in part by Charlie's Fund. The Company is currently working to advance this new drug candidate into clinical trials under an investigational new drug application (IND) in the United States and an investigational medicinal product dossier (IMPD) in Europe.

About Duchenne Muscular Dystrophy (DMD)

DMD is the most common fatal genetic disorder to affect children around the world. Approximately one in every 3,500 boys worldwide is afflicted with Duchenne Muscular Dystrophy with 20,000 new cases reported each year. It is a devastating and incurable muscle-wasting disease associated with specific inborn errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Symptoms usually appear in male children before age six. Progressive muscle weakness of the legs and pelvis eventually spreads to the arms, neck, and other areas. By age 10, braces may be required for walking, and most patients are confined to a wheelchair by age 12. Eventually, this progresses to complete paralysis and increasing difficulty in breathing. The condition is terminal and death usually occurs before the age of 30. The outpatient cost of care for a non-ambulatory DMD boy is among the highest of any disease. There is currently no cure for DMD, but for the first time in decades, there are promising therapies in or moving into development.

About Action Duchenne

Action Duchenne (formally Parent Project UK) was set up by Duchenne families in 2001 to promote new research for a cure for Duchenne. The charity has a strong record in funding research and has to date funded 9 major projects costing over £1m and has been a leading partner in the £1.6m DoH MDEX project. These projects have enabled much needed early work to be completed on exon skipping and other therapeutic approaches.

Action Duchenne holds an international conference every year to bring together researchers and families to exchange new research developments and provide a vital meeting venue for scientists.

In 2005 Action Duchenne launched the Duchenne Registry, the first National Duchenne database that holds gene information of people living with Duchenne and can be used to speed up the recruitment of patients for clinical trials. In 2006 Action Duchenne launched a comprehensive learning and behaviour toolkit for use by parents and education professionals. For more information please visit: www.actionduchenne.org

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

AVI Press and Investor Contact:
Julie Rathbun
Investor Relations
(541) 224-2575
Investorrelations@avibio.com

Action Duchenne Contacts:
Nick Catlin
CEO
Action Duchenne
+44 (0) 20 8556 9955
Email: nick@actionduchenne.orgAndreina West
PR Artistry
+44 (0) 1491 639500
email: Andreina@pra-ltd.co.uk

die Aktie läuft gut.

ohne erkennbare News.

ist das evtl. der Grund für den Anstieg ?

dabei?

AVI BioPharma Announces Second Quarter 2009 Financial Results Conference Call
For Immediate Release
CORVALLIS, OR — August 3, 2009 — AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, will hold a conference call to report second quarter 2009 financial results on Monday, August 10, 2009, at 9:30 a.m. Eastern time (6:30 a.m. Pacific time).

Individuals interested in listening to the live conference call may do so by dialing 800-967-7135 toll free within the United States and Canada, or 719-457-2603 for international callers.

A replay of the call will be available by dialing 888-203-1112 toll free within the U.S. and Canada or 719-457-0820 for international callers. The passcode for the replay is 4026242. In addition, a recording of the call will be available within approximately 24 hours at www.avibio.com.

www.nasdaq.com//aspxcontent/...;cdtime=08%2F10%2F2009+8%3A00AM

quotes.nasdaq.com/asp/...ote.asp?symbol=AVII&selected=AVII

und starker Anstieg heute. News bisher nicht erkennbar.

der Anstig ist erfreulich, die Frage ist nur, ob es sich um einen kurzen Ausbruch handelt.

kommt bei so einem Volumen die News noch. Da haben vermutlich Leute gekauft die vorher etwas wußten, anders kann ich es mir nicht erklären.

und Novavax auch.

gestern. Fängt ja in den USA gut an.

http://www.marketwatch.com/investing/stock/AVII?siteid=mktw

mit Novavax. Die haben positive Phase II Ergebnisse.

und dann noch so ein schöner Anstieg.

www.marketwatch.com/story/...-investment-conference-2009-09-02

handelt ihr die aktie?

in NY, nur dort ist der Markt entsprechend liquide.

und auch das Volumen hat zugelegt.

quotes.nasdaq.com/asp/...ote.asp?symbol=AVII&selected=AVII

Preliminary safety data from AVI's current systemic Phase 1b/2 clinical trial of AVI-4658 in patients with DMD was also presented by Dr. Stephen B. Shrewsbury, Chief Medical Officer and Senior Vice President of Preclinical, Clinical and Regulatory Affairs of AVI at the World Muscle Society (WMS) in Geneva on September 12, 2009. This presentation highlighted the study's early findings, which showed AVI-4658 to be well tolerated in patients in the first two completed dosing cohorts and the study's three ongoing dosing cohorts, where there have been no confirmed, drug-related adverse events or safety issues. These preliminary data further support the study's dose escalation to the final patient cohort at 20 mg/kg, which has been agreed in principal by the UK Regulatory Authority (MHRA) and the Ethics Committee and will be preceded by a Data Safety Monitoring Board review of data from the highest dose cohort currently being treated (10 mg/kg).

"These positive safety findings are exciting and promising, both for AVI-4658 and, most importantly, for patients and their families living with DMD," said Dr. Shrewsbury. "With no currently approved disease modifying therapies available to treat this fatal genetic disease, the progress being made in SSO-induced exon skipping is key. Insights into long-term safety and chronic dosing regimens could represent a crucial step forward in developing a safe and effective lifelong treatment for patients living with DMD."

The Phase 1 proof of principle, single dose escalation study tested the effect of an intramuscular injection of AVI-4658 in boys with DMD. The primary and secondary endpoints were safety and efficacy of AVI-4658, respectively. Each patient received an injection of 0.09 mg or 0.9 mg of AVI-4658, which is a novel phosphorodiamidate morpholino oligomer (PMO), into the exterior digitorum brevis muscle of one foot and an injection of saline as placebo into the corresponding muscle of the opposite foot to provide an internal treatment comparison. Three to four weeks later, each injected muscle was biopsied and examined for evidence of dystrophin production. Results demonstrated that injection of AVI-4658 elicited exon 51 skipping and dystrophin production in a dose dependent manner in all treated patients. Specifically, 44-79% of EDB fibers were dystrophin-positive, relative to contralateral muscle background and dystrophin levels seen in patients treated with AVI-4658 (equivalent to 42% of the dystrophin levels seen in each normal muscle cell) exceeded the levels achieved in a recent 2'O-methyl-phosphorothioate oligomer (2'O-Me P) DMD clinical trial. Importantly, AVI-4658 was well tolerated, with no adverse events related to the administration of the drug. These findings were also recently published in Lancet Neurology online and will appear in the journal's October 2009 print issue.

The currently ongoing Phase 1b/2 dose-finding clinical trial is evaluating the systemic delivery of AVI-4658. This is an open label, 12-week safety trial that includes measures of drug efficacy and pharmacokinetics. To date, four of the six dosing cohorts have been successfully completed and the fifth dosing cohort (10 mg/kg) is ongoing. Preliminary data presented at the WMS show that AVI-4658 has been well tolerated with very few mild and transient drug-related adverse events and no serious adverse events. Further, the independent Data Safety Monitoring Board (DSMB) has approved each of the trial's dose escalations and -- with DSMB approval -- AVI could begin dosing on the sixth and final cohort (20 mg/kg) shortly. Importantly, dosing of the fifth and sixth cohort out to 12 weeks will exceed both dose level and duration of dosing previously studied by other researchers with the alternative 2'O-Me P approach. AVI believes that this encouraging and growing safety profile, duration of exposure and approved dose escalations are extremely important clinical advances for its PMO chemistry approach as any dose-limiting toxicity for any drug, could severely limit the effectiveness of a DMD therapy in this chronic condition where treatment must start in childhood and probably continue for life.

"It has been very pleasing to work on this project from its beginning and to be part of its early clinical success -- showing the safety and efficacy of AVI-4658 when administered intramuscularly," said Professor Francesco Muntoni, the study's lead investigator and head of the MDEX consortium in the UK, which performed the study. "We are delighted to be recruiting DMD patients into the ongoing systemic study and to see that treatment is being well tolerated. The children in this trial and their families have been enthusiastic in their participation in these studies and we would like to thank them for taking part in this important clinical work."

The Phase 1b/2 clinical trial is being conducted in London, UK at the UCL Institute of Child Health / Great Ormond Street Hospital NHS Trust facilities and at the Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK, which is the coordinating center for the European Treat Neuromuscular Diseases (Treat-NMD) initiative. The clinical costs for the trial are provided, in part, by the UK Medical Research Council.

About Duchenne Muscular Dystrophy (DMD)

DMD is one of the most common fatal genetic disorders to affect children around the world. Approximately one in every 3,500 boys worldwide is afflicted with Duchenne Muscular Dystrophy with 20,000 new cases reported each year. It is a devastating and incurable muscle-wasting disease associated with specific inborn errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Symptoms usually appear in male children by age three. Progressive muscle weakness of the legs and pelvis eventually spreads to the arms, neck, and other areas. By age 10, braces may be required for walking, and most patients are confined to a wheelchair by age 12. Eventually, this progresses to complete paralysis and increasing difficulty in breathing requiring ventilatory support. The condition is terminal and death usually occurs before the age of 30. The outpatient cost of care for a non-ambulatory DMD boy is among the highest of any disease. There is currently no cure for DMD, but for the first time ever, there are promising therapies in or moving into development.

About the MDEX Consortium

The MDEX consortium led by Professor Francesco Muntoni, is a multidisciplinary enterprise to promote translational research into muscular dystrophies, and is formed by the clinical groups of Professor Francesco Muntoni (UCL Institute of Child Health) and Professor Kate Bushby and Professor Volker Straub (Newcastle University), and scientists from Imperial College London (Professor Dominic Wells), UCL Institute of Child Health (Dr. Jennifer Morgan), Royal Holloway University of London (Professor George Dickson), Oxford University (Dr. Matthew Wood) and University of Western Australia (Professor Steve Wilton). In addition, the charities Muscular Dystrophy Campaign (MDC), Action Duchenne and Duchenne Family Support Group also participate in the Consortium. For more information, visit www.mdex.org.uk.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

AVI Press and Investor Contact:
Julie Rathbun
Investor Relations
(541) 224-2575
Investorrelations@avibio.com

AVI BioPharma Gets Expanded Contract Funding Of About $11.5 Mln From U.S. Department Of Defense - Quick Facts

Monday October 05, 2009 11:29:00 EDT

(RTTNews) - Monday, AVI BioPharma Inc. (AVII) received an expanded contract funding of approximately $11.5 million from the Defense Threat Reduction Agency's or DTRA Transformational Medical Technologies Initiative or TMTI. The contract is to support development of the Investigational New Drug or IND data package for its candidate drug, AVI-7012, to treat Junin virus infection.


The company noted that to date, the United States Department of Defense has contracted it for work potentially worth up to $45 million for the development of AVI's RNA-based drug candidates to treat Ebola, Marburg and Junin virus infections.


The company added that it received a safe to proceed allowance from the United States Food and Drug Administration for IND applications for clinical safety trials of its two lead products to treat Ebola and Marburg virus infections. These INDs represent the first TMTI supported drug candidates targeting bioterrorism agents to receive FDA IND allowance.


For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2009 RTTNews.com, Inc. All Rights Reserved

www.quote.com/news/story.action?id=RTT910051129001139

... geht es mal wieder leicht aufwärts.

Mal sehen was die Schweinegrippe noch für AVII bringt...

... 1,55 zu 1,75 USD!

Treatment with AVI-4658 in the three patients in the 2.0 and 4.0 mg/kg cohorts led to accurate skipping of exon 51, which is believed to be necessary to restore the mRNA reading frame for functional dystrophin expression in patients with this class of mutations. Analysis of post-treatment biopsies by the reverse transcription-polymerase chain reaction showed a new lower molecular weight band of RNA resulting from the intended skipping, or exclusion, of exon 51. The intensity of the higher molecular weight band (which included exon 51) was correspondingly reduced. In one of the patients at the 2.0 mg/kg dose, the appearance of skipped mRNA was accompanied by a robust increase in expression of dystrophin protein in the post treatment samples using both western blot and immunofluorescent analysis. Western blot analysis detected a fivefold increase in dystrophin expression, from 0.9% to 5.3% of normal. Immunofluorescent analysis of the muscle biopsies from this patient showed an increase in the percentage of dystrophin positive muscle fibers from 1% pre-treatment to 21% in the post-treatment biopsy. Quantitative intensity analysis of the amount of dystrophin per fiber in patient samples before and after drug treatment showed a sevenfold increase in dystrophin. When compared to the level of dystrophin in normal muscle fibers, the dystrophin content per patient fiber went from 5% pre-treatment to 37% in the post-treatment biopsy.

"I am very encouraged by the evidence of accurate skipping of exon 51 in three treated patients," stated Prof. Francesco Muntoni, Professor of Pediatric Neurology and Head of the Dubowitz Neuromuscular Centre at the UCL Institute of Child Health, London, England and the trial's lead investigator. "These results suggest that we are on the right path towards developing a drug that could play a role in the treatment of DMD. The fact that one patient at the 2 mg/kg dose showed significant expression of dystrophin protein leads us to expect greater levels of dystrophin expression following treatment with the higher doses of 10.0 mg/kg and 20.0 mg/kg of AVI-4658, which are currently underway in the trial."

Clinical Trial Design and Update

Study 28 is a Phase 1b/2 open label, dose-ranging clinical trial assessing the safety, tolerability, pharmacokinetics and exploratory efficacy of AVI-4658 in ambulatory DMD boys between the ages of 5 and 15 years of age who have an error in the gene coding for dystrophin that could be treated by skipping exon 51. Patients are dosed once per week for 12 weeks by intravenous infusion. Nineteen patients have been enrolled in total and assigned to one of six dose cohorts: 0.5, 1.0, 2.0, 4.0, 10.0 or 20.0 mg/kg. After completion of dosing, patients are followed for a further 14 weeks. The primary objective of the trial is to assess the safety of AVI-4658 at these doses over the 26-week duration of the trial.

To date, 9 of 10 patients in the first four cohorts (0.5 through 4.0 mg/kg) have completed dosing. A single patient (in the 4 mg/kg cohort) withdrew from treatment due to DMD-related cardiomyopathy (now stabilized and believed not to be drug related). An additional patient was enrolled at 4 mg/kg but has not yet completed dosing. All 8 patients in the fifth and sixth cohorts, receiving 10 or 20 mg/kg respectively, have initiated dosing.

Data from patients dosed to date demonstrate that AVI-4658 continues to be generally very well tolerated. Adverse events reported to date are mostly mild, unrelated to drug treatment and transient. In the patients who completed dosing, two serious adverse events, both deemed unrelated to AVI-4658, were reported in different patients after they completed their 12-week treatment period and during the 14-week follow-up period.

Studies Towards US IND

AVI has completed a series of 12-week preclinical studies of AVI-4658 under Good Laboratory Practice (GLP) conditions required to open an Investigational New Drug (IND) application in the US. The studies tested doses up to 960 mg/kg in both mdx and wild type mice, and up to 320 mg/kg in non-human primates, both doses being the maximum feasible single doses in these animals. In all cases the PMO was well tolerated at doses equivalent to 80 mg/kg and 110 mg/kg in humans respectively (based on standard allometric scaling), suggesting the potential for a wide therapeutic index.

An additional GLP study of AVI-4225 PMO, to skip exon 23, in the mdx mouse has also been completed, with similar encouraging reports of good tolerability. The histopathology is currently being reviewed but initial reports suggest that the muscles of treated mice show improvement over the 12 weeks of study.

"AVI-4658 continues to demonstrate the good safety profile associated with PMO-based drug candidates. Data from the recently completed series of preclinical studies required to open an IND in the US suggest that this good tolerability is likely to continue at higher doses," stated Stephen B. Shrewsbury, M.D., Senior Vice President and Chief Medical Officer, AVI BioPharma, Inc. "This is critically important given that any DMD drug based on exon skipping is expected to be administered regularly over the entire course of a patient's life."

The clinical trial of AVI-4658 is being conducted in London, UK at the UCL Institute of Child Health / Great Ormond Street Hospital NHS Trust facilities by members of the MDEX Consortium led by Professor Muntoni and by Professor Kate Bushby at the Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK, which is the coordinating center for the European Treat Neuromuscular Diseases (Treat-NMD) initiative. The clinical costs for the trial are provided, in part, by the UK Medical Research Council.

About Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD) is one of the most common fatal genetic disorders to affect children around the world. Approximately one in every 3,500 boys worldwide is afflicted with DMD with 20,000 new cases reported each year. It is a devastating and incurable muscle-wasting disease associated with specific inborn errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Symptoms usually appear in male children by age three. Progressive muscle weakness of the legs and pelvis eventually spreads to the arms, neck, and other areas. By age 10, braces may be required for walking, and most patients are confined to a wheelchair by age 12. Eventually, this progresses to complete paralysis and increasing difficulty in breathing requiring ventilatory support. The condition is terminal and death usually occurs before the age of 30. The outpatient cost of care for a non-ambulatory DMD boy is among the highest of any disease. There is currently no cure for DMD, but for the first time ever, there are promising therapies in or moving into development.

Conference Call

AVI management will hold a conference call to review the initial data from the ongoing Phase 1b/2 clinical trial on Tuesday, December 22, 2009, at 8:30 AM Eastern time (5:30 AM Pacific Time).

Individuals interested in listening to the live conference call may do so by dialing 877-879-6209 toll free within the United States and Canada, or 719-325-4794 for international callers. A replay of the call will be available by dialing 888-203-1112 toll free within the United States and Canada, or 719-457-0820 for international callers. The passcode for the replay is 1823048. In addition, a recording of the call will be available within approximately 24 hours at www.avibio.com.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy, including an ongoing systemic Phase 1b/2 clinical trial of exon skipping with AVI-4658. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as Junín, influenza, HCV or Dengue viruses. For more information, visit www.avibio.com.

About the MDEX Consortium

The MDEX consortium led by Professor Francesco Muntoni, is a multidisciplinary enterprise to promote translational research into muscular dystrophies, and is formed by the clinical groups of Professor Francesco Muntoni (UCL Institute of Child Health) and Professor Kate Bushby and Professor Volker Straub (Newcastle University), and scientists from Imperial College London (Professor Dominic Wells), UCL Institute of Child Health (Dr. Jennifer Morgan), Royal Holloway University of London (Professor George Dickson), Oxford University (Dr. Matthew Wood) and University of Western Australia (Professor Steve Wilton). In addition, the charities Muscular Dystrophy Campaign (MDC), Action Duchenne and Duchenne Family Support Group also participate in the Consortium. For more information, visit www.mdex.org.uk.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

Products granted an orphan drug designation by the EMEA are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions that affect no more than five in 10,000 people in the EU, or are medicines which, for economic reasons, would unlikely be developed without incentives. The aim of the EU orphan medicines designation is to stimulate research and development of medicinal products for rare diseases by providing incentives to the pharmaceutical industry. This initiative helps to give patients suffering from rare diseases access to the same quality of treatment as other patients. Applications for designation of orphan medicines are reviewed by the EMEA through the Committee for Orphan Medicinal Products.

About Duchenne Muscular Dystrophy

DMD is one of the most common fatal genetic disorders to affect children around the world. Approximately one in every 3,500 boys worldwide is afflicted with DMD with 20,000 new cases reported each year. It is a devastating and incurable muscle-wasting disease associated with specific inborn errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Symptoms usually appear in male children by age three. Progressive muscle weakness of the legs and pelvis eventually spreads to the arms, neck, and other areas. By age 10, braces may be required for walking, and most patients are confined to a wheelchair by age 12. Eventually, this progresses to complete paralysis and increasing difficulty in breathing requiring ventilatory support. The condition is terminal and death usually occurs before the age of 30. The outpatient cost of care for a non-ambulatory DMD boy is among the highest of any disease. There is currently no cure for DMD, but for the first time ever, there are promising therapies in or moving into development.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA–based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI’s antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI’s RNA–based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy, including an ongoing systemic Phase 1b/2 clinical trial of exon skipping with AVI-4658. AVI’s antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as Junín, influenza, HCV or Dengue viruses. For more information, visit www.avibio.com.

# # #

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward–looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings.

www.avibio.com/news_detail.php?newsId=0071

“The exon-skipping strategies being developed by AVI offer the greatest prospect for meaningful clinical therapies for the majority of boys and young men afflicted with this cruel disorder. We are gratified by the partnership with CureDuchenne, Children’s National Medical Center and AVI,” commented Joel Wood, President and Founder of the Foundation to Eradicate Duchenne. “Speaking as the parent of a 12-year-old with DMD, I’m tremendously optimistic that we can punch through the remaining hurdles in time for this generation of DMD kids. This is an anxious and exciting time in the history of this disorder.”

AVI-4658 Study 28 Overview

AVI is currently conducting a dose-finding clinical trial evaluating the systemic delivery of AVI-4658. Known as Study 28, this ongoing Phase 1b/2 open label clinical trial is assessing the safety, tolerability, pharmacokinetics and exploratory efficacy of AVI-4658 in ambulatory DMD boys between the ages of 5 and 15 years of age who have an error in the gene coding for dystrophin that could be treated by skipping exon 51. Patients are dosed once per week for 12 weeks by intravenous infusion. Nineteen patients were enrolled in total and assigned to one of six dose cohorts: 0.5, 1.0, 2.0, 4.0, 10.0 or 20.0 mg/kg. After completion of dosing, patients are followed for a further 14 weeks. The primary objective of the trial is to assess the safety of AVI-4658 at these doses over the 26-week duration of the trial. The trial is fully enrolled and the final cohort is being dosed.

Data from patients dosed to date demonstrate that AVI-4658 continues to be generally well tolerated. Adverse events reported to date are mostly mild, unrelated to drug treatment and transient. In the patients who completed dosing, two serious adverse events, both deemed unrelated to AVI-4658, were reported in different patients after they completed their 12-week treatment period and during the 14-week follow-up period.

In Study 28, efficacy data from patients in the first four dose cohorts who completed 12 weeks of treatment demonstrates that all patients in the 2 and 4 mg/kg cohorts (3 of 3 in total) showed correctly spliced mRNA for the dystrophin protein. One of these patients, a boy in the 2mg/kg cohort, showed a robust treatment response: a fivefold increase in dystrophin expression (from 0.9% to 5.3% of normal) on a western blot analysis, and an increase from 1% pre-treatment to 21%, in the percentage of dystrophin positive muscle fibers in patient muscle biopsies as measured by immunofluorescence analysis. After completing treatment, no RNA or protein expression signal was detected in patients in the lowest dose cohorts, 0.5 mg/kg or 1.0 mg/kg. Restoration of functional dystrophin expression is considered critical for successful treatment of DMD.

Studies Towards US IND

AVI has completed a series of 12-week preclinical studies of AVI-4658 under Good Laboratory Practice (GLP) conditions required to open an Investigational New Drug (IND) application in the US. The studies tested doses up to 960 mg/kg in both mdx and wild type mice, and up to 320 mg/kg in non-human primates, both doses being the maximum feasible single doses in these animals. In all cases the PMO was well tolerated at doses equivalent to 80 mg/kg and 110 mg/kg in humans respectively (based on standard allometric scaling), suggesting the potential for a wide therapeutic index. These studies were conducted by AVI in cooperation with Eric Hoffman, Ph.D., of the Children’s National Medical Center, Washington DC, and supported by a U.S. Defense Department grant.

An additional GLP study of AVI-4225 PMO, to skip exon 23, in the mdx mouse has also been completed, with similar encouraging reports of good tolerability. The histopathology is currently being reviewed but initial reports suggest that the muscles of treated mice show improvement over the 12 weeks of study.

About Duchenne Muscular Dystrophy


Duchenne Muscular Dystrophy (DMD) is one of the most common fatal genetic disorders to affect children around the world. Approximately one in every 3,500 boys worldwide is afflicted with DMD with 20,000 new cases reported each year. It is a devastating and incurable muscle-wasting disease associated with specific inborn errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Symptoms usually appear in male children by age three. Progressive muscle weakness of the legs and pelvis eventually spreads to the arms, neck, and other areas. By age 10, braces may be required for walking, and most patients are confined to a wheelchair by age 12. Eventually, this progresses to complete paralysis and increasing difficulty in breathing requiring ventilatory support. The condition is terminal and death usually occurs before the age of 30. The outpatient cost of care for a non-ambulatory DMD boy is among the highest of any disease. There is currently no cure for DMD, but for the first time ever, there are promising therapies in or moving into development.

About CureDuchenne

CureDuchenne is a nonprofit organization that raises awareness and funds research specifically aimed at taking on Duchenne Muscular Dystrophy (DMD). By working closely with the world’s leading DMD scientists CureDuchenne works to determine the most viable research projects that will accelerate the clinical trial process and bring potential life saving drugs to help this generation of young boys living with the deadly disease.  Our vision is our name…to Cure Duchenne. Learn more at: www.cureduchenne.org.

About The Foundation to Eradicate Duchenne

The Foundation to Eradicate Duchenne is a 501c3 charitable organization established in 2001 to pursue therapeutics for Duchenne Muscular Dystrophy. It is headquartered in Alexandria, VA. Since its inception, the FED has funded millions of dollars in aggressive research and is a principal funder of the Cooperative International Neuromuscular Research Group, an international clinical trials network founded at Children’s National Medical Center in Washington, DC.

About Children’s National Medical Center/Children’s Research Institute

Children’s National Medical Center, located in Washington, DC, is a leader in the development of innovative new treatments for childhood illness and injury. Children’s has been serving the nation’s children for more than 135 years. Children’s National is consistently ranked among the best pediatric hospitals by U.S.News & World Report and the Leapfrog Group. For more information, visit www.ChildrensNational.org. Children’s Research Institute, the academic arm of Children’s National Medical Center, encompasses the translational, clinical, and community research efforts of the institution. Learn more about Children’s Research Institute at www.childrensnational.org/research.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA–based medicines utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI’s antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI’s RNA–based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy, including an ongoing systemic Phase 1b/2 clinical trial of exon skipping with AVI-4658. AVI’s antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as Junín, influenza, HCV or Dengue viruses. For more information, visit www.avibio.com.

# # #

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings.

www.avibio.com/news_detail.php?newsId=0072

The material terms of this contract were initially announced by AVI on May 11, 2009 in a regulatory filing (8-K) with the U.S. Securities and Exchange Commission regarding an original funding award of up to $5.1 million, which was finalized at $4.1 million. The approximately $4.0 million in increased funding support announced today was initially disclosed in a regulatory filing (8-K) on March 26, 2010 and is in addition to any funding earned under the contract announced on May 11, 2009. The objective of the contract is to accomplish the preclinical development of one or more medical countermeasures based on AVI's proprietary PMOplus™ chemistry.

About Pandemic H1N1 Influenza

On June 11, 2009 the World Health Organization declared a pandemic of H1N1 influenza. The virus was first detected in people in the U.S. in April 2009 and was referred to as "swine flu" because many of the genes in the virus were very similar to those found in flu viruses that circulate in pigs (swine). Illness with the 2009 H1N1 virus has ranged from mild to severe. Symptoms include fever, cough, runny nose, headache, chills and fatigue. Many people infected with H1N1 also have respiratory symptoms without a fever. Severe illness and deaths have occurred as a result of illness associated with the virus. The Centers for Disease Control and Prevention (CDC) estimated that between April 2009 and January 16, 2010 there were up to 84 million cases of H1N1 infection in the U.S. The CDC also estimated that there were up to 378,000 H1N1-related hospitalizations in the U.S. during the same time period.

About Defense Threat Reduction Agency

The Defense Threat Reduction Agency (DTRA) was founded in 1998 to integrate and focus the capabilities of the Department of Defense that address the weapons of mass destruction (WMD) threat. The mission of the DTRA is to safeguard America and its allies from WMD (e.g. chemical, biological, radiological, nuclear, and high yield explosives) by providing capabilities to reduce, eliminate, and counter the threat, and mitigate its effects. Under DTRA, Department of Defense resources, expertise and capabilities are combined to ensure the United States remains ready and able to address the present and future WMD threats. For more information on DTRA, visit www.dtra.mil/.

About Transformational Medical Technologies Initiative

The TMTI was created by the DoD to protect the Warfighter from emerging and genetically altered biological threats by discovering and developing a wide range of medical countermeasures through enhanced medical research, development, test and evaluation programs. The TMTI Program Office is matrixed from the Joint Science and Technology Office -- DTRA and Joint Program Executive Office -- Chemical and Biological Defense, with oversight from the Office of the Secretary of Defense. For more information on TMTI, visit www.tmti-cbdefense.org.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based medicines utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy, including an ongoing systemic Phase 1b/2 clinical trial of exon skipping with AVI-4658. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as Junín, influenza, HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.



Read more: www.nasdaq.com//aspxcontent/...8%2F2010+8%3A00AM#ixzz0mbzKVdaN

Data reported today for the patients in the 10 and 20 mg/kg drug-treatment cohorts completing the 12 weekly doses (8 of 8 patients) showed consistent skipping of exon 51 in the dystrophin mRNA, providing evidence of systemic biologic activity of AVI-4658.
Three patients, one each in the 2.0, 10 and 20 mg/kg cohorts, demonstrated substantial generation of new dystrophin-positive muscle fibers, including the first ever reported generation of dystrophin-positive muscle fibers of more than 50% of normal in a patient following systemic administration of a drug.
All 8 patients in the 10 and 20 mg/kg cohorts demonstrated generation of new dystrophin-positive muscle fibers.
The three patients, one each in the 2.0, 10 and 20 mg/kg cohorts, demonstrating substantial generation of new dystrophin-positive muscle fibers had multiple fold increases in dystrophin protein expression measured by Western blot over baseline, with patients in the 20 mg/kg cohort demonstrating the highest increases. These three patients also had noted increases in dystrophin per fiber.
"These results are very encouraging. The muscle cells of the patients at the higher levels had clear qualitative and quantitative changes in their dystrophin expression and this was not associated with any sign of inflammation or immune response against dystrophin-positive fibers. To look at the muscle biopsies of these treated patients under the microscope, and appreciate the new production of dystrophin compared to the pre-treated muscles, reveals a very different picture from that typically observed in DMD patients," stated Prof. Francesco Muntoni, Professor of Pediatric Neurology and Head of the Dubowitz Neuromuscular Centre at the UCL Institute of Child Health, London, England and the trial's lead investigator. "This trial demonstrates the potential of a systemically administered drug to induce a substantial novel dystrophin protein expression in multiple patients with DMD at levels that may produce a clinically meaningful effect on the course of the disease. Based on these results and on how the patients tolerated the study drug, I believe that AVI-4658 has the potential to become a disease modifying drug in the treatment of DMD."

Study Details

AVI-4658 was generally well tolerated in all Study 28 patients, and there has been no evidence of anti-dystrophin antibodies or T and B cell infiltration. In the patients completing dosing, two serious adverse events (one instance each of post operative nausea and vomiting, and an ankle fracture), both deemed unrelated to AVI-4658, were reported in different patients after they completed their 12-week treatment period and during the 14-week follow-up period of the trial.

Treatment with AVI-4658 in all patients in the 10 and 20 mg/kg cohorts showed consistent skipping of exon 51, which is believed necessary to restore the mRNA reading frame and dystrophin expression in a substantial subgroup of patients with specific mutations. Analysis of post-treatment biopsies by reverse transcription-polymerase chain reaction (RT-PCR) confirmed the new mRNA resulting from the intended skipping, or exclusion, of exon 51.

All 8 patients in the 10 and 20 mg/kg cohorts treated with AVI-4658 demonstrated generation of new dystrophin-positive muscle fibers as measured by immunofluorescent analysis of their muscle biopsies.

Of note, three patients, one patient in each of the 2.0, 10 and 20 mg/kg cohorts, demonstrated substantial generation of new dystrophin-positive muscle fibers, which increased from 1% to 21%, 1% to 15%, and 3% to 55% of normal, respectively, when comparing pre treatment to post treatment samples. These three patients demonstrated a noted increase in dystrophin per fiber as determined by immunofluorescent analysis as well as multiple fold increases in dystrophin protein expression measured by Western blot over baseline. Patients in the 20 mg/kg cohort demonstrated the greatest fold increases when compared to the other cohorts measured by Western blot.

Overall, patients in the 10 and 20 mg/kg cohorts, both quantitatively and qualitatively, had more uniform and widespread dystrophin-positive fiber distribution than patients receiving lower doses. Additionally, responses of patients in the 20 mg/kg cohort appeared better than the patients in the 10 mg/kg cohort.

"Having supported exon-skipping technology for more than a decade and from its earliest stages, we're delighted that AVI BioPharma has demonstrated that systemic administration of an exon-skipping drug can bring a substantial increase in dystrophin-positive muscle fibers in patients with Duchenne muscular dystrophy," says Valerie Cwik M.D., Muscular Dystrophy Association Executive Vice President, Research and Medical Director. "Many questions remain, including optimal dosing, and treatment applicability for specific mutations, but this is clearly an important advance."

Clinical Trial Design and Update

AVI-4658 is an RNA-based therapeutic employing AVI's novel phosphorodiamidate morpholino oligomer (PMO) based chemistry which can work by exon skipping. It is being developed as a systemic treatment for patients with DMD. Study 28 is a Phase 1b/2 open label, dose-ranging, clinical trial assessing the safety, tolerability, pharmacokinetics and exploratory efficacy of AVI-4658 in ambulatory patients with DMD between the ages of 5 and 15 years of age who have an error in the gene coding for dystrophin that can be treated by skipping exon 51. Patients were dosed once per week for 12 weeks by intravenous infusion. Nineteen patients were enrolled in total and assigned to one of six dose cohorts: 0.5, 1.0, 2.0, 4.0, 10.0 or 20.0 mg/kg. After completion of dosing, patients are followed for a further 14 weeks. The primary objective of the trial is to assess the safety of AVI-4658 at these doses over the 26-week duration of the trial. All patients completed dosing. Some patients in the highest dose cohort remain in the 14 week follow-up period.

"The topline results reported today are very promising and suggest an overall very favorable profile, which is important considering that any DMD therapy will likely be chronic, administered to children and potentially life-long. Of particular importance was that AVI-4658 was generally well tolerated as a systemic treatment in all Study 28 patients, which is consistent with our data demonstrating that AVI-4658 was well tolerated in preclinical studies up to an equivalent human dose of approximately 100 mg/kg," stated Stephen B. Shrewsbury, M.D., Senior Vice President and Chief Medical Officer, AVI BioPharma, Inc. "Moving forward, we will complete our data analysis and we intend to review the clinical data with key opinion leaders and work with regulatory authorities to finalize our plans for additional clinical development, including optimizing a dosing regimen to provide a more consistent result across potentially treatable patients."

The clinical trial of AVI-4658 is being conducted in London, UK at the UCL Institute of Child Health / Great Ormond Street Hospital NHS Trust facilities by members of the MDEX Consortium led by Professor Muntoni and by Professor Kate Bushby at the Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK, which is the coordinating center for the European Network of Excellence TREAT-NMD. The clinical costs for the trial are provided, in part, by the UK Medical Research Council.

About Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) is one of the most common fatal genetic disorders to affect children around the world. Approximately one in every 3,500 boys worldwide is affected with DMD. Girls are rarely affected by the disorder. DMD is a devastating and incurable muscle-wasting disease associated with specific inborn errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Symptoms usually appear in children by age three. Progressive muscle weakness of the legs and pelvis eventually spreads to the arms, neck, and other areas. By age 10, braces may be required for walking, and most patients require full-time use of a wheelchair by age 12. Eventually, this progresses to complete paralysis and increasing difficulty in breathing due to respiratory muscle dysfunction requiring ventilatory support, and cardiac muscle dysfunction leading to heart failure. The condition is terminal and death usually occurs before the age of 30. The outpatient cost of care for a non-ambulatory DMD patient is very high. There is currently no cure for DMD, but for the first time ever there are promising therapies in, or moving into, development.

Conference Call
AVI management will hold a conference call to review the topline biopsy data from the ongoing Phase 1b/2 clinical trial on June 2, 2010, at 8:30 AM Eastern time (5:30 AM Pacific Time).

The conference call may be accessed by dialing 866.202.0886 for domestic callers and 617.213.8841 for international callers. The passcode for the call is 97738469 and please specify to the operator that you would like to join the "AVI BioPharma conference call." The conference call will be webcast live under the events section of AVI's website at www.avibio.com, and will be archived there following the call. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About the MDEX Consortium
The MDEX consortium led by Professor Francesco Muntoni, is a multidisciplinary enterprise to promote translational research into muscular dystrophies, and is formed by the clinical groups of Professor Francesco Muntoni (UCL Institute of Child Health) and Professor Kate Bushby and Professor Volker Straub (Newcastle University), and scientists from Imperial College London (Professor Dominic Wells), UCL Institute of Child Health (Dr. Jennifer Morgan), Royal Holloway University of London (Professor George Dickson), Oxford University (Dr. Matthew Wood) and University of Western Australia (Professor Steve Wilton). In addition, the charities Muscular Dystrophy Campaign (MDC), Action Duchenne and Duchenne Family Support Group also participate in the Consortium. For more information, visit www.mdex.org.uk.

About AVI BioPharma
AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (phosphorodiamidate morpholino oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy, including an ongoing systemic Phase 1b/2 clinical trial of exon skipping with AVI-4658. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as Junín, influenza, HCV or Dengue viruses. For more information, visit www.avibio.com.

AVI BioPharma to Present at ThinkEquity's Mid Year Check-Up on Healthcare Conference


BOTHELL, WA -- (MARKET WIRE) -- 06/10/10 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that the company is scheduled to present at ThinkEquity's Mid Year Check-Up on Healthcare Conference, June 16, 2010, at 1:00 p.m. Eastern Time in New York City. J. David Boyle II, AVI's Interim President and Chief Executive Officer, and Chief Financial Officer, is scheduled to provide a company overview.

The conference presentation will be webcast live under the events section of AVI's website at www.avibio.com, and will be archived there following the presentation. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based therapeutics utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy, including an ongoing systemic Phase 1b/2 clinical trial of exon skipping with AVI-4658. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as Junín, influenza, HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.



Read more: www.nasdaq.com//aspxcontent/...0%2F2010+2%3A00PM#ixzz0qUWlbA9B

Hallo Zusammen

Erst mal, bin neu hier, komme aus der Schweiz und aus einem Schweizer Börsenforum. Ariva scheint mir ein grosses User-Volumen, sowie kompetente Trader drin zu haben. Deshalb entschied ich mich, hier mich mal anzumelden.

Bin seit letzter Woche in AVII investiert. Habe mir AVII genau studiert, TA gemacht, sowie das News-push-Verhalten genau angeschaut, was eigentlich nicht so wichtig ist. Das Orderbook habe ich mir letzte Woche auch eine Weile Tag für Tag angeschaut. Vorerst habe ich mal einen mittleren Einsatz gewagt (<12k). Einige Tage später, also letzten Freitag konnte ich mir das nicht mehr entgehen lassen und habe nochmals investiert.

Die Aktie könnte meiner Meinung nach eine saubere performance hinlegen, daher empfehle ich sich mal den biotech Titel anzuschauen.

www.google.com/finance?q=NASDAQ:AVII

PS: Gibt es hier einen Vorstellungsthread?
Manche werden mich bereits wohl kennen, da ich den gleichen Username in einem CH-Forum trage.

...ist mir auch aufgefallen. Es gab allerdings im August des letzten Jahres Tage, da wurden sogar zwei über 10 Millionen und einmal über 20 Millionen an Aktien gehandelt.

http://www.ariva.de/quote/...009-08-31&secu=5314&boerse_id=40

PS: Wenn Du Dich vorstellen möchtest, tue dies doch einfach im Talk-Forum. Du kannst dort gern einen entsprechenden Thread eröffnen.

Ich habe hier mal das US-Orderbook gepostet. Leider ist der Beitrag irgendwie völlig weg. Wurde der Beitrag gelöscht, oder ist hier irgendwo ein Fehler unterlaufen. Das Orderbook dürfte ich ja publizieren dürfen , da ich für dieses bezahle.

...ist Dir wohl misslungen...

Wenn es gelöscht worden wäre, würde man dies im Thread sehen. Das Posten des Orderbuches ist m.W. auch erlaubt.

Wieder 2 Millionen Umsatz heute. Nur leider haben wir fast auf Tagestief geschlossen...

AVII geht momentan mit dem Dow Jones mehr oder weniger mit. Nur heute nicht so ganz. Aber das Interesse ist gemäss Orderbook noch gut. Der Chart zeigt mir einen baldigen starken Aufschwung. Momentan wird ein Support gebildet.


Also eben der Grund für den anstehenden Kursanstieg sind die sehr positiven "trials" des Medikaments. FDA Entscheid wird daher sehr wahrscheinlich positiv ausfallen. Daher wird es sehr wahrscheinlich dann den Run beim Approval nicht riesig geben, da dies langfristig enthalten ist.

Gegen Schluss hat AVII kräftig an Volumen zugenommen. Nach Börsenschluss kam ein Volumen von ca. 1 Million zusammen. Eigentlich recht komisch, weil dies nicht üblich, bzw. selten bei AVII ist. Da läuft irgend etwas, so mein Gefühl.

 

AVI BioPharma Opens Investigational New Drug (IND) Application for AVI-4658 in Duchenne Muscular Dystrophy

 

BOTHELL, WA -- (MARKET WIRE) -- 07/07/10 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced that following review by the U.S. Food and Drug Administration the Company's Investigational New Drug (IND) application for AVI-4658 is open. AVI-4658 is AVI's lead drug candidate being developed as a systemically administered treatment for a substantial subgroup of patients with Duchenne muscular dystrophy (DMD), a genetic muscle wasting disease caused by failure to produce dystrophin. AVI plans to initiate a Phase 1b/2 clinical trial in DMD in the U.S. this year.

The intended site for the planned U.S. based study is Nationwide Children's Hospital in Columbus, Ohio, with Jerry R. Mendell, M.D. as the Principal Investigator. The clinical program design is being reviewed in consultation with Dr. Mendell, co-investigator Kevin Flanigan, M.D., and other DMD key opinion leaders. It is anticipated that future clinical evaluation will explore increasing doses of AVI-4658 considering the generally well tolerated nature of the drug candidate as exhibited in the clinical and preclinical studies to date, and the substantial, but variable, increases in dystrophin measurements demonstrated in patients with DMD in the U.K. based Phase 1b/2 clinical trial.

"We are actively working with scientific and medical experts and regulatory authorities to finalize plans for our U.S. based Phase 1b/2 study as we complete the collection and analysis of clinical data from the recent U.K. trial of AVI-4658," stated Stephen B. Shrewsbury, M.D., Senior Vice President and Chief Medical Officer, AVI BioPharma, Inc. "The results we have reported to date are very promising and suggest an overall very favorable safety profile. As we continue the clinical evaluation of systemically administered AVI-4658, I remain optimistic about its potential to induce consistent, substantial novel dystrophin protein expression in patients with DMD."

AVI-4658 is an RNA-based therapeutic employing AVI's novel phosphorodiamidate morpholino oligomer (PMO) based chemistry and exon skipping technologies. It is being developed as a systemic treatment for patients with DMD.

About Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD) is one of the most common fatal genetic disorders to affect children around the world. Approximately one in every 3,500 boys worldwide is affected with DMD. Girls are rarely affected by the disorder. DMD is a devastating and incurable muscle-wasting disease associated with specific inborn errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Symptoms usually appear in children by age three. Progressive muscle weakness of the legs and pelvis eventually spreads to the arms, neck, and other areas. By age 10, braces may be required for walking, and most patients require full-time use of a wheelchair by age 12. Eventually, this progresses to complete paralysis and increasing difficulty in breathing due to respiratory muscle dysfunction requiring ventilatory support, and cardiac muscle dysfunction leading to heart failure. The condition is terminal and death usually occurs before the age of 30. The outpatient cost of care for a non-ambulatory DMD patient is very high. There is currently no cure for DMD, but for the first time ever there are promising therapies in, or moving into, development.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based medicines utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy, including an ongoing systemic Phase 1b/2 clinical trial of exon skipping with AVI-4658. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as Junín, influenza, HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

Read more: http://www.nasdaq.com/aspx/...00MRKTWIREUSPR____0638257#ixzz0tE4dRu7o

Jetzt kommt auf jeden Fall mal richtig Geld in die Kasse. Der neue Vertrag mit dem U.S. Department of Defense Chemical and Biological Defense Programm hat ein Volumen von 291 Millionen USD, wobei die Marktkapitalisierung bei gerademal bei ca. 215 Millionen USD liegt.

Hier die Meldung vom 16.07.2010:

"AVI BioPharma Wins $291 Mln Defense Contract - Stocks to Watch


(RTTNews) - AVI BioPharma Inc. (AVII) said it won a $291 million contract from the U.S. Department of Defense Chemical and Biological Defense Program.

The contract was awarded for advanced development of hemorrhagic fever virus therapeutic candidates, AVI-6002 and AVI-6003, for Ebola and Marburg viruses.

As per the contract, AVI Biopharma will get up to $80 million immediately, with possibility of further funding up to $291 million.

AVII closed Thursday's regular trading at $1.63 on Nasdaq. In Friday's pre-market session, the stock is trading up more than 22%.

For comments and feedback: contact editorial@rttnews.com



Read more: www.nasdaq.com/aspx/...847RTTRADERUSEQUITY_0631#ixzz0uAp3M2QM"

Der Chart sieht interessant aus... ==> Watchlist

Gru$$
Der Pennystockzocker

www.thestreet.com/_nasdaq/story/10812353/1/...EE&cm_ite=NA

schließt der Share tatsächlich im Minus.

im Wesentlichen war der Inhalt der Meldung auch schon seit Freitag bekannt...

Ich bleibe hier erstmal längerfristig drin, da es m.M. über kurz oder lang zu einer Neubewertung kommen wird.

Der Titel ist wohl vielen aus den Augen verloren gegangen. Bei dem Titel muss man aufpassen. Das Interesse ist noch nicht riesig und daher habe ich das Paket gestaffelt gleich beim >20% jump verkauft. Da sind es einfach die News die die Aktie pushen. Ich werde aber wieder bei günstigeren Preisen einsteigen.

AVII, da wird noch einiges an performance dazu kommen.

Mal auf die WL nehmen...

heute -25% nach gemischten Studienergebnissen

www.marketwatch.com/story/...udy-results-2012-04-02?siteid=rss

Pursuant to Listing Rule 5810(c)(3)(A), AVI has 180 calendar days, or until November 27, 2012, to regain compliance with the minimum bid price requirement. If at any time before this date AVI's common stock has a closing bid price of $1.00 or more for a minimum of 10 consecutive business days, NASDAQ staff will notify AVI that it has regained compliance.

www.benzinga.com/news/12/06/2636947/...id-price-non-compliance

www.nasdaq.com/symbol/srpt/real-time

+ 154% zur Zeit!

Hier die News dazu:

www.nasdaq.com/article/...en-in-phase-iib-trial-20120724-00584

Gestern: Top Wetten; heute: GWB und AVI...

multi-bagger time

falscher thread! tut mir leid... Gruß

Wer kennt diese Aktie?

dieses Jahr noch hingeht. :-)